Azenta (AZTA) 10-Q 10 May 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - $ / shares	6 Months Ended
	Mar. 31, 2023	May 08, 2023
Cover [Abstract]
Entity Central Index Key	0000933974
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	000-25434
Entity Registrant Name	AZENTA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3040660
Entity Address, Address Line One	200 Summit Drive
Entity Address, Address Line Two	6th Floor
Entity Address, City or Town	Burlington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01803
City Area Code	978
Local Phone Number	262-2626
Title of 12(b) Security	Common Stock, $0.01 par value
Entity Listing, Par Value Per Share	$ 0.01
Trading Symbol	AZTA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		65,166,558
Current Fiscal Year End Date	--09-30
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Current assets
Cash and cash equivalents	$ 667,365	$ 658,274
Short-term marketable securities	513,651	911,764
Accounts receivable, net of allowance for expected credit losses ($7,696 and $5,162, respectively)	167,960	163,758
Inventories	150,727	85,544
Derivative asset	1,278	124,789
Short-term restricted cash	4,021	382,596
Prepaid expenses and other current assets	80,732	132,621
Total current assets	1,585,734	2,459,346
Property, plant and equipment, net	215,301	154,470
Long-term marketable securities	266,176	352,020
Long-term deferred tax assets	490	1,169
Goodwill	790,494	513,623
Intangible assets, net	323,927	178,401
Other assets	67,692	57,093
Total assets	3,249,814	3,716,122
Current liabilities
Accounts payable	45,306	38,654
Deferred revenue	46,048	39,748
Accrued warranty and retrofit costs	5,380	2,890
Accrued compensation and benefits	27,632	41,898
Accrued income taxes payable	5,228	28,419
Accrued expenses and other current liabilities	83,050	78,937
Total current liabilities	212,644	230,546
Long-term tax reserves	1,720	1,684
Long-term deferred tax liabilities	70,104	64,555
Long-term pension liabilities	280	261
Long-term operating lease liabilities	57,137	49,227
Other long-term liabilities	12,702	6,463
Total liabilities	354,587	352,736
Stockholders' equity
Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding
Common stock, $0.01 par value - 125,000,000 shares authorized, 82,602,702 shares issued and 69,147,387 shares outstanding at March 31, 2023, 88,482,125 shares issued and 75,020,256 shares outstanding at September 30, 2022	826	885
Additional paid-in capital	1,495,118	1,992,017
Accumulated other comprehensive loss	(38,870)	(83,916)
Treasury stock, at cost - 13,461,869 shares at March 31, 2023 and September 30, 2022	(200,956)	(200,956)
Retained earnings	1,639,109	1,655,356
Total stockholders' equity	2,895,227	3,363,386
Total liabilities and stockholders' equity	$ 3,249,814	$ 3,716,122

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Allowance for expected credit losses	$ 7,696	$ 5,162
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	125,000,000	125,000,000
Common stock, shares issued (in shares)	82,602,702	88,482,125
Common stock, shares outstanding (in shares)	69,147,387	75,020,256
Treasury Stock, Shares [Abstract]
Treasury stock, shares (in shares)	13,461,869	13,461,869

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Revenue
Total revenue	$ 148,401	$ 145,544	$ 326,767	$ 285,196
Cost of revenue
Total cost of revenue	95,165	74,719	199,666	147,327
Gross profit	53,236	70,825	127,101	137,869
Operating expenses
Research and development	8,520	6,896	16,056	13,381
Selling, general and administrative	73,339	67,915	165,891	128,626
Contingent consideration - fair value adjustments	(17,145)	600	(17,145)	600
Restructuring charges	1,499	122	2,961	295
Total operating expenses	66,213	75,533	167,763	142,902
Operating loss	(12,977)	(4,708)	(40,662)	(5,033)
Interest income	10,394	3,076	21,059	3,111
Interest expense		(1,555)		(2,010)
Loss on extinguishment of debt		(632)		(632)
Other income (expense)	(2,668)	(1,170)	(1,523)	(2,248)
Loss before income taxes	(5,251)	(4,989)	(21,126)	(6,812)
Income tax benefit	(3,260)	(3,173)	(7,900)	(7,853)
Income (loss) from continuing operations	(1,991)	(1,816)	(13,226)	1,041
Income (loss) from discontinued operations, net of tax	(2,936)	2,121,690	(2,936)	2,162,152
Net income (loss)	$ (4,927)	$ 2,119,874	$ (16,162)	$ 2,163,193
Basic net income (loss) per share:
Income (loss) from continuing operations (in dollars per share)	$ (0.03)	$ (0.02)	$ (0.19)	$ 0.01
Income (loss) from discontinued operations, net of tax (in dollars per share)	(0.04)	28.31	(0.04)	28.90
Basic net income (loss) per share (in dollars per share)	(0.07)	28.28	(0.23)	28.91
Diluted net income (loss) per share:
Income (loss) from continuing operations (in dollars per share)	(0.03)	(0.02)	(0.19)	0.01
Income (loss) from discontinued operations, net of tax (in dollars per share)	(0.04)	28.31	(0.04)	28.77
Diluted net income (loss) per share (in dollars per share)	$ (0.07)	$ 28.28	$ (0.23)	$ 28.79
Weighted average shares used in computing net income (loss) per share:
Basic (in shares)	69,111	74,958	70,858	74,823
Diluted (in shares)	69,111	74,958	70,858	75,145
Products
Revenue
Total revenue	$ 51,917	$ 49,449	$ 137,715	$ 95,318
Cost of revenue
Total cost of revenue	40,009	24,953	94,108	49,475
Services
Revenue
Total revenue	96,484	96,095	189,052	189,878
Cost of revenue
Total cost of revenue	$ 55,156	$ 49,766	$ 105,558	$ 97,852

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (4,927)	$ 2,119,874	$ (16,162)	$ 2,163,193
Other comprehensive income (loss), net of tax:
Foreign currency translation reclassification adjustments included in income from discontinued operations		(16,567)		(16,567)
Net investment hedge currency translation adjustment, net of tax effects of ($4,531) and ($24,239) for the three and six months ended March 31, 2023 and net of tax effects of $3,524 for the three and six months ended March 31, 2022	(13,133)	7,149	(70,260)	7,149
Foreign currency translation adjustments	33,850	(18,907)	111,264	(14,980)
Changes in unrealized gain on marketable securities, net of tax effects of $858 and $1,395 for the three and six months ended March 31, 2023 and net of tax effects of ($874) and ($874) for the three months and six months ended March 31, 2022	2,487	(3,306)	4,042	(2,432)
Actuarial gains, net of tax effects of $0 and $0 during the three and six months ended March 31, 2023, $0 and $0 during the three and six months ended March 31, 2022		84		81
Total other comprehensive income (loss), net of tax	23,204	(31,547)	45,046	(26,749)
Comprehensive income (loss)	$ 18,277	$ 2,088,327	$ 28,884	$ 2,136,444

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent, Parenthetical Disclosure [Abstract]
Net investment hedge currency translation adjustment, tax	$ (4,531)	$ 3,524	$ (24,239)	$ 3,524
Changes in unrealized losses on marketable securities, tax	858	(874)	1,395	(874)
Actuarial gains (losses), tax	$ 0	$ 0	$ 0	$ 0

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net income (loss)	$ (16,162)	$ 2,163,193
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	42,140	26,005
Stock-based compensation	6,096	7,230
Contingent consideration adjustment	(17,145)	600
Amortization of deferred financing costs		66
Amortization of premium on marketable securities and deferred financing costs	(5,284)
Deferred income taxes	(20,843)	11,054
Loss on extinguishment of debt		632
Purchase accounting impact on inventory	5,781
(Gain) loss on disposals of property, plant and equipment	31	(30)
Gain on divestiture, net of tax		(2,130,351)
Fees paid stemming from divestiture		(52,461)
Changes in operating assets and liabilities, net of acquisitions and divestiture:
Accounts receivable	23,925	(456)
Inventories	(11,504)	(55,033)
Accounts payable	(5,677)	(7,906)
Deferred revenue	3,625	5,215
Accrued warranty and retrofit costs	622	(198)
Accrued compensation and tax withholdings	(21,797)	10,875
Accrued restructuring costs	820	(113)
Other current assets and liabilities	(23,798)	(34,061)
Net cash used in operating activities	(39,170)	(55,739)
Cash flows from investing activities
Purchases of property, plant and equipment	(21,705)	(44,326)
Purchases of technology intangibles		(4,000)
Purchases of marketable securities	(233,584)	(1,074,428)
Sales and maturities of marketable securities	728,171	3,710
Net Investment hedge settlement	29,313
Proceeds from divestiture, net of cash transferred		2,927,245
Acquisitions, net of cash acquired	(387,665)
Net cash provided by investing activities	114,530	1,808,201
Cash flows from financing activities
Proceeds from issuance of common stock		3,461
Payments of financing costs		(312)
Principal payments on debt		(49,725)
Common stock dividends paid		(7,494)
Payment for contingent consideration related to acquisition		(9,400)
Payments of finance leases	(230)
Stock repurchase	(500,000)
Withholding tax payments on net share settlements on equity awards	(4,906)
Net cash used in financing activities	(505,136)	(63,470)
Effects of exchange rate changes on cash and cash equivalents	60,355	(25,372)
Net decrease in cash, cash equivalents and restricted cash	(369,421)	1,663,620
Cash, cash equivalents and restricted cash, beginning of period	1,041,296	285,333
Cash, cash equivalents and restricted cash, end of period	671,875	1,948,953
Supplemental disclosures:
Cash paid for income taxes, net	$ 35,286	$ 20,782

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Cash and cash equivalents of continuing operations	$ 667,365	$ 658,274
Short-term restricted cash	4,021	382,596
Long-term restricted cash included in other assets	489	426
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$ 671,875	$ 1,041,296
Restricted Cash, Noncurrent, Statement of Financial Position	Other assets	Other assets

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)	Treasury Stock	Total
Beginning Balance at Sep. 30, 2021	$ 878	$ 1,976,112	$ 19,351	$ (470,051)	$ (200,956)	$ 1,325,334
Beginning Balance (in shares) at Sep. 30, 2021	87,808,922
Increase (Decrease) in Stockholders' Equity
Shares issued under restricted stock and purchase plans, net	$ 7	3,455				3,462
Shares issued under restricted stock and purchase plans, net (in shares)	641,161
Stock-based compensation		7,229				7,229
Common stock dividends declared				(7,493)		(7,493)
Net investment hedge currency translation adjustment, net of tax effect			7,149			7,149
Foreign currency translation reclassification adjustments included in income from discontinued operations			(16,567)			(16,567)
Foreign currency translation adjustments			(14,980)			(14,980)
Changes in unrealized gains (losses) on marketable securities, net of tax			(2,432)			(2,432)
Actuarial loss, net of tax effects			81			81
Net income (loss)				2,163,193		2,163,193
Ending Balance at Mar. 31, 2022	$ 885	1,986,796	(7,398)	1,685,649	(200,956)	3,464,976
Ending Balance (in shares) at Mar. 31, 2022	88,450,083
Beginning Balance at Dec. 31, 2021	$ 884	1,977,571	24,149	(434,225)	(200,956)	1,367,423
Beginning Balance (in shares) at Dec. 31, 2021	88,375,410
Increase (Decrease) in Stockholders' Equity
Shares issued under restricted stock and purchase plans, net	$ 1	3,460				3,461
Shares issued under restricted stock and purchase plans, net (in shares)	74,673
Stock-based compensation		5,765				5,765
Net investment hedge currency translation adjustment, net of tax effect			7,149			7,149
Foreign currency translation reclassification adjustments included in income from discontinued operations			(16,567)			(16,567)
Foreign currency translation adjustments			(18,907)			(18,907)
Changes in unrealized gains (losses) on marketable securities, net of tax			(3,306)			(3,306)
Actuarial loss, net of tax effects			84			84
Net income (loss)				2,119,874		2,119,874
Ending Balance at Mar. 31, 2022	$ 885	1,986,796	(7,398)	1,685,649	(200,956)	3,464,976
Ending Balance (in shares) at Mar. 31, 2022	88,450,083
Beginning Balance at Sep. 30, 2022	$ 885	1,992,017	(83,916)	1,655,356	(200,956)	$ 3,363,386
Beginning Balance (in shares) at Sep. 30, 2022	88,482,125					75,020,256
Increase (Decrease) in Stockholders' Equity
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes		1,573			(4,629)	$ (3,056)
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes (in shares)	210,711
Accelerated share repurchase					(500,000)	(500,000)
Accelerated share repurchase (in shares)	(6,090,134)
Retirement of treasury shares	$ (59)	(504,568)			504,629	2
Stock-based compensation		6,096				6,096
Net investment hedge currency translation adjustment, net of tax effect			(70,260)			(70,260)
Foreign currency translation adjustments			111,264			111,264
Changes in unrealized gains (losses) on marketable securities, net of tax			4,042			4,042
Net income (loss)				(16,162)		(16,162)
Other				(85)		(85)
Ending Balance at Mar. 31, 2023	$ 826	1,495,118	(38,870)	1,639,109	(200,956)	$ 2,895,227
Ending Balance (in shares) at Mar. 31, 2023	82,602,702					69,147,387
Beginning Balance at Dec. 31, 2022	$ 824	1,489,554	(62,074)	1,644,041	(200,956)	$ 2,871,389
Beginning Balance (in shares) at Dec. 31, 2022	82,515,917
Increase (Decrease) in Stockholders' Equity
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes		1,573				1,573
Shares issued under restricted stock and purchase plans, net of shares withheld for employee taxes (in shares)	86,785
Retirement of treasury shares	$ 2					2
Stock-based compensation		3,991				3,991
Net investment hedge currency translation adjustment, net of tax effect			(13,133)			(13,133)
Foreign currency translation adjustments			33,850			33,850
Changes in unrealized gains (losses) on marketable securities, net of tax			2,487			2,487
Net income (loss)				(4,927)		(4,927)
Other				(5)		(5)
Ending Balance at Mar. 31, 2023	$ 826	$ 1,495,118	$ (38,870)	$ 1,639,109	$ (200,956)	$ 2,895,227
Ending Balance (in shares) at Mar. 31, 2023	82,602,702					69,147,387

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) $ in Thousands	6 Months Ended
	Mar. 31, 2022 USD ($) $ / shares
Statement of Stockholders' Equity [Abstract]
Dividend declared per share (in dollars per share) | $ / shares	$ 0.10
Net investment hedge currency translation adjustment, tax	$ 3,524
Changes in unrealized losses on marketable securities, tax	(874)
Actuarial gains (losses), tax	$ 0

Nature of the Operation

Nature of the Operation	6 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Operation	1. Nature of Operation Azenta, Inc. (“Azenta”, or the “Company”) is a leading global provider of life sciences sample exploration and management solutions for the life sciences market. The Company supports its customers from research to clinical development with its sample management, automated storage, and genomic services expertise to help bring impactful therapies to market faster. Risks and Uncertainties The Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial market conditions, fluctuations in customer demand, acceptance of new products, development by its of new technological innovations, risk of disruption in its supply chain, the implementation of tariffs and export controls, inflation, dependence on key personnel, protection of proprietary technology, and compliance with domestic and foreign regulatory authorities and agencies. The COVID-19 pandemic has had varying impacts on our financial results. In the first two years of the pandemic, any marginal adverse impact was more than offset by incremental orders related to virus research, COVID testing and vaccine development and commercialization in 2021 and through the first half of 2022. There has been limited COVID-related demand after the second fiscal quarter of 2022, and therefore, our revenue trends since then have been negatively impacted when compared to prior periods. Future impacts on the Company’s financial results are not fully determinable, as the continuing impact of the pandemic on the economy and markets which the Company serves is as yet unknown, but will be dependent, in part, on future variants of the virus and vaccine effectiveness against these variants and new or prolonged government responses to the pandemic. The Company’s financial results will also depend on variables including reduced demand from its customers, the degree that the supply chain may be constrained which could impact its delivery of products and services and the potential negative impact on its operations if there is an outbreak among the Company’s employees, as well as the amount of incremental demand caused by research and treatments in the areas of COVID-19 or related threats. ​

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation and Basis of Presentation The accompanying Consolidated Financial Statements include the accounts of the Company and its majority-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of March 31, 2023, and its results of operations for the three months and six months ended March 31, 2023 and 2022, and cash flows for the six months ended March 31, 2023 and 2022, respectively. The consolidated balance sheet at September 30, 2022 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission for the fiscal year ended September 30, 2022 (the “2022 Annual Report on Form 10-K”). Use of Estimates The preparation of unaudited consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates are associated with recording accounts receivable, inventories, goodwill, intangible assets other than goodwill, contingent consideration liabilities related to business combinations, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue over time, and stock-based compensation expense. The Company assesses the estimates on an ongoing basis and records changes in estimates in the period they occur and become known. Actual results could differ from these estimates. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, including results of operations and financial condition will depend on future developments that are highly uncertain. This includes results from new information that may emerge concerning COVID-19 and any actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within the analysis of its financial statements. ​ Business Combinations The Company accounts for business acquisitions using the purchase method of accounting, in accordance with which assets acquired and liabilities assumed are recorded at their respective fair values at the acquisition date. The fair value of the consideration paid, including contingent consideration, is assigned to the assets acquired and liabilities assumed based on their respective fair values. Goodwill represents the excess of the purchase price over the estimated fair values of the assets acquired and liabilities assumed. ​ Significant judgment is used in determining fair values of assets acquired and liabilities assumed and contingent consideration, as well as intangibles and their estimated useful lives. Fair value and useful life determinations may be based on, among other factors, estimates of future expected cash flows and appropriate discount rates used in computing present values. These judgments may materially impact the estimates used in allocating acquisition date fair values to assets acquired and liabilities assumed, as well as our current and future operating results. Actual results may vary from these estimates that may result in adjustments to goodwill and acquisition date fair values of assets and liabilities during a measurement period or upon a final determination of asset and liability fair values, whichever occurs first. Adjustments to fair values of assets and liabilities made after the end of the measurement period are recorded within our operating results. ​ Changes in the fair value of contingent consideration resulting from a change in the underlying inputs are recognized in results of operations until the arrangement is settled. ​ Foreign Currency Translation Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange gains (losses) generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other income (expenses)” in the Company’s Consolidated Statements of Operations. Net foreign currency transaction and remeasurement losses were $0.9 million and $1.2 million for the three months ended March 31, 2023 and 2022, respectively. Net foreign currency transaction and remeasurement losses were The determination of the functional currency of the Company’s subsidiaries is based on their financial and operational environment and is the local currency of the Company’s foreign subsidiaries. The subsidiaries’ assets and liabilities are translated into the reporting currency at period-end exchange rates, while revenue, expenses, gains and losses are translated at the average exchange rates during the period. Gains and losses from foreign currency translations are recorded in “Accumulated other comprehensive income (loss)” in the Company’s Consolidated Balance Sheets and presented as “Foreign currency translation adjustments” in the Company’s Consolidated Statements of Comprehensive Income (Loss). Derivative Financial Instruments The Company has transactions and balances denominated in currencies other than the functional currency of the transacting entity. Most of these transactions carry foreign exchange risk in Germany, the United Kingdom and China. The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations. The arrangements typically mature in three months or less and they do not qualify for hedge accounting. Net gains and losses related to these contracts are recorded as a component of “Other income (expenses)” in the accompanying unaudited Consolidated Statements of Operations and are as follows for the three and six months ended March 31, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ March 31, ​ March 31, ​ ​ 2023 2022 2023 2022 Realized gains (losses) on derivatives not designated as hedging instruments ​ $ (533) ​ $ 1,125 ​ $ (2,112) ​ $ 1,054 ​ ​ The fair values of the forward contracts are recorded in the accompanying unaudited Consolidated Balance Sheets as “Prepaid expenses and other current assets” and “Accrued expenses and other current liabilities”. Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy described below due to a lack of an active market for these contracts. Hedging Activities On February 1, 2022, the Company entered into a cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged approximately $1.03 billion for approximately €915 million at a weighted average interest rate of approximately 1.196% . The designated notional amount is $960 million and the actual interest rate is 1.283% . The 1.283% rate was in the range of the market value for that day and is the true interest rate on the notional amount. The Company designated the cross-currency swap as a hedge of net investments against one of our Euro denominated subsidiaries which requires an exchange of the notional amounts at maturity. At the maturity of the cross currency-swap on February 1, 2023, the Company delivered a notional amount of €852 million and received a notional amount of $960 million at an exchange rate of 1.1261 , which includes realization of a gain of $29.3 million, which was recorded in “Accumulated other comprehensive income (loss)”. On February 1, 2023, the Company entered into another cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged approximately . The Company designated the cross-currency swap as a hedge of net investments against one of its Euro denominated subsidiaries, which requires an exchange of the notional amounts at maturity on February 1, 2024. The cross-currency swaps are marked to market at each reporting period, representing the fair values of the cross-currency swap and any changes in fair value are recognized as a component of “Accumulated other comprehensive items, net,” on the Consolidated Statements of Comprehensive Income (Loss). Interest accrued on the cross-currency swap is recorded within “Interest income” on the Consolidated Statements of Operations. For the three and six months ended March 31, 2023, the Company recorded a net loss of $13.1 and $70.3 million, respectively to “Accumulated other comprehensive income (loss)” and recorded “Interest income” of $2.2 million and $5.3 million on these instrument for the three and six months ended March 31, 2023, respectively. Fair Value Measurement The Company measures certain financial assets and liabilities, including cash equivalents, available-for-sale securities, accounts receivable, accounts payable, contingent consideration liability and derivative instruments at fair value. The Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement (“ASC 820”) establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Available-for-sale securities and derivative instruments are measured at fair value based on quoted market prices or observable inputs other than quoted market prices for identical or similar assets or liabilities. Contingent consideration liabilities that are recorded at fair value are based on level 3 inputs. The carrying amounts of cash equivalents, accounts receivable and accounts payable approximate their fair value due to their short-term nature. Accounts Receivable and Allowance for Expected Credit Losses and Sales Returns Trade accounts receivable do not bear interest and are recorded at the invoiced amount. The Company maintains an allowance for expected credit losses representing its best estimate of expected credit losses related to its existing accounts receivable and their net realizable value. The Company determines the allowance based on a number of factors, including an evaluation of customer credit worthiness, the age of the outstanding receivables, economic trends, historical experience and other information over the payment periods. The Company reviews and adjusts the allowance for expected credit losses on a quarterly basis. Accounts receivable balances are written off against the allowance for expected credit losses when the Company determines that the balances are not recoverable. Provisions for expected credit losses are recorded in “Selling, general and administrative” expenses in the Consolidated Statements of Operations. The Company determines the allowance for sales returns based on its best estimate of expected customer returns. Provisions for sales returns are recorded in “Revenue” in the Consolidated Statements of Operations. The Company does not have any off-balance-sheet credit exposure related to its customers. Leases The Company has operating leases for real estate and non-real estate and finance leases for non-real estate. The classification of a lease as operating or finance and the determination of the right-of-use asset (“ROU asset”) and lease liability are determined at lease inception. The ROU asset represents the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company’s lease agreements may contain lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. Fixed payments for non-lease components are combined with lease payments and accounted for as a single lease component which increases the amount of the ROU asset and liability. The ROU asset for operating leases is included within “Other assets” and the ROU asset for finance leases is included within “Property, plant, and equipment, net” in the accompanying unaudited Consolidated Balance Sheets. The short-term lease liabilities for both operating leases and finance leases are included within “Accrued expenses and other current liabilities” in the accompanying unaudited Consolidated Balance Sheets. The long-term lease liabilities for operating leases and finance leases are included within “Long-term operating lease liabilities”, and “Other long-term liabilities”, respectively, in the accompanying unaudited Consolidated Balance Sheets. Recently Issued Accounting Pronouncements In March 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting . In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope. The ASUs provide temporary optional expedients and exceptions to the GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates. The provisions of the ASUs are only available until December 31, 2022, when the reference rate replacement activity was expected to be completed. There were no significant accounting impacts on the Company’s consolidated financial statements and related disclosures as a result of the adoption of these ASU’s. “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,” Recently Adopted Accounting Pronouncements In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance . The amendment in this ASU requires disclosures to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021. The Company will adopt the provisions of this ASU in fiscal 2023 . ​ In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . ASU 2021-08 requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”) . Under current GAAP, an acquirer generally recognizes such items at fair value on the acquisition date. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The standard should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted the guidance during the first quarter of fiscal year 2022 . The impact of the adoption of this ASU is immaterial to the Company’s consolidated financial statements. In October 2020, the FASB issued ASU 2020-10, Codification Improvements . The amendments in this ASU represent changes to clarify certain ASCs, correct unintended application of guidance, or make minor improvements to certain ASCs that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. ASU 2020-10 is effective for annual periods beginning after December 15, 2020 and interim periods within those annual periods, with early adoption permitted. The amendments in this ASU should be applied retrospectively. This ASU did not affect the Company's consolidated financial statements or disclosures. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . In June 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) In August 2018, the FASB issued ASU 2018-14, Disclosure Framework — Changes to the Disclosure Requirements for Defined Benefit Plans , which amends ASC 715, Compensation – Retirement Benefits to add, remove, and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The amendments require additional disclosure for the weighted-average interest crediting rates, a narrative description of the reasons for significant gains and losses, and an explanation of any other significant changes in the benefit obligation or plan assets. The amendment removes disclosure requirements for accumulated other comprehensive income or loss expected to be recognized over the next year, information about plan assets to be returned to the entity, and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits. The ASU is effective for fiscal years ending after December 15, 2020. Early adoption was permitted. The ASU does not amend the interim disclosure requirements of ASC 715-20. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740) , which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 clarifying and amending existing guidance. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2020. Early adoption was permitted. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU. Other For further information with regard to the Company’s significant accounting policies, please refer to Note 2 “Summary of Significant Accounting Policies” to the Company’s consolidated financial statements included in the 2022 Annual Report on Form 10-K.

Discontinued Operations

Discontinued Operations	6 Months Ended
	Mar. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	3. Discontinued Operations Disposition of the Semiconductor Automation Business On September 20, 2021, the Company entered into a definitive agreement to sell its semiconductor automation business to Thomas H. Lee Partners, L.P. (“THL”) and the Company determined that the semiconductor automation business met the criteria to be classified as a discontinued operation and, as a result, its historical financial results are reflected in the Company’s financial statements as a discontinued operation, and assets and liabilities were classified as assets and liabilities held for sale. On February 1, 2022, the Company completed the sale of the semiconductor automation business for $2.9 billion in cash. As part of the transaction, the Company recorded an $18.1 million liability related to retention bonuses and cash settled stock-based awards for former employees of the Company that were conveyed with the transaction. The Company paid million of these payments during the year ended September 30, 2022 and remitted the remaining payments to THL in November 2022, and THL directly paid the Company’s former employees. Following the completion of the sale, the Company no longer serves the semiconductor market. In connection with the closing of the sale, the Company and THL entered into a transition services agreement, to which both the Company and THL will provide each other with certain transition services related to finance and accounting, information technology, human resources, compliance, facilities, legal and research and development support, for time periods ranging from three . In addition, the Company entered into separate lease agreements for leases back to the Company for portions of the facilities that previously served as its corporate headquarters in Chelmsford, Massachusetts, and were sold to THL as part of the sale agreement. Each lease provides for a term of The following table presents the financial results of discontinued operations with respect to the semiconductor automation business (in thousands). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ ​ Six Months Ended March 31, ​ ​ ​ 2022 ​ ​ 2022 Revenue ​ ​ ​ ​ ​ ​ ​ ​ Products ​ ​ ​ $ 56,722 ​ ​ $ 244,962 Services ​ ​ ​ ​ 4,038 ​ ​ ​ 19,468 Total revenue ​ ​ ​ ​ 60,760 ​ ​ ​ 264,430 Cost of revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ Products ​ ​ ​ ​ 33,568 ​ ​ ​ 141,165 Services ​ ​ ​ ​ 2,850 ​ ​ ​ 11,159 Total cost of revenue ​ ​ ​ ​ 36,418 ​ ​ ​ 152,324 Gross profit ​ ​ ​ ​ 24,342 ​ ​ ​ 112,106 Operating expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ ​ ​ ​ 4,746 ​ ​ ​ 18,486 Selling, general and administrative ​ ​ ​ ​ 7,466 ​ ​ ​ 30,142 Total operating expenses ​ ​ ​ ​ 12,212 ​ ​ ​ 48,628 Operating income ​ ​ ​ ​ 12,130 ​ ​ ​ 63,478 Gain on divestiture ​ ​ ​ ​ 2,561,420 ​ ​ ​ 2,561,374 Income before income taxes ​ ​ ​ ​ 2,573,550 ​ ​ ​ 2,624,852 Income tax provision ​ ​ ​ ​ 451,860 ​ ​ ​ 462,700 Net income from discontinued operations ​ ​ ​ $ 2,121,690 ​ ​ $ 2,162,152 ​ During the three months ended March 31, 2023, the Company recorded a $0.4 million loss on divestiture. The following table presents the significant non-cash items and capital expenditures for the discontinued operations with respect to the semiconductor automation business that are included in the Consolidated Statements of Cash Flows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ Six Months Ended March 31, ​ ​ ​ ​ ​ 2022 ​ ​ ​ 2022 Depreciation and amortization ​ ​ ​ $ - ​ ​ $ - Capital expenditures ​ ​ ​ $ 579 ​ ​ $ 2,862 Stock-based compensation ​ ​ ​ $ 3,109 ​ ​ $ 8,032 ​ ​ ​ ​ ​ ​ Disposition of the Semiconductor Cryogenics Business During the three months ended March 31, 2023, the Company recorded a $2.5 million loss on divestiture of the Semiconductor Cryogenics business, due to the accrual of a liability related to a claim.

Marketable Securities

Marketable Securities	6 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	4. Marketable Securities The Company invests in marketable securities that are classified as available-for-sale and records them at fair value in the accompanying unaudited Consolidated Balance Sheets. Marketable securities reported as current assets represent investments that mature within one year from the balance sheet date. Long-term marketable securities represent investments with maturity dates greater than one year from the balance sheet date. Unrealized gains and losses are excluded from earnings and reported as a separate component of “Accumulated other comprehensive income (loss)” in the accompanying unaudited Consolidated Balance Sheets until the security is sold or matures. Gains or losses realized from sales of marketable securities are computed based on the specific identification method and recognized as a component of “Other income (expenses)” in the accompanying unaudited Consolidated Statements of Operations. The Company had sales and maturities of marketable securities of $121.0 million and $728.2 million in the three and six months ended March 31, 2023, respectively. There were insignificant sales and maturities of marketable securities in each of the three and six months ended March 31, 2022, respectively. There were insignificant realized gain or loss in each of the three and six months ended March 31, 2023 and 2022. The following is a summary of the amortized cost and the fair value, including accrued interest receivable as well as unrealized gains (losses) on the short-term and long-term marketable securities as of March 31, 2023 and September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross Gross ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ ​ ​ ​ Cost ​ Losses ​ Gains ​ Fair Value March 31, 2023: ​ ​ ​ ​ U.S. Treasury securities and obligations of U.S. government agencies $ 435,258 ​ $ (3,672) ​ $ 31 $ 431,617 Bank certificates of deposits ​ ​ 10,355 ​ ​ (187) ​ ​ 1 ​ ​ 10,169 Corporate securities ​ ​ 341,868 ​ ​ (5,370) ​ ​ — ​ ​ 336,498 Municipal securities ​ 1,544 ​ ​ (1) ​ ​ — ​ 1,543 ​ ​ $ 789,025 ​ $ (9,230) ​ $ 32 ​ $ 779,827 September 30, 2022: ​ ​ ​ ​ ​ U.S. Treasury securities and obligations of U.S. government agencies ​ $ 804,774 $ (6,163) $ 21 ​ $ 798,632 Bank certificates of deposits ​ ​ 8,335 ​ ​ (158) ​ ​ 1 ​ ​ 8,178 Corporate securities ​ ​ 406,270 ​ ​ (8,113) ​ ​ — ​ ​ 398,157 Municipal securities ​ 59,043 ​ ​ (226) ​ ​ — ​ 58,817 ​ ​ $ 1,278,422 ​ $ (14,660) ​ $ 22 ​ $ 1,263,784 ​ The fair values of the marketable securities by contractual maturities at March 31, 2023 are presented below (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortized ​ ​ ​ ​ ​ ​ Cost ​ ​ Fair Value Due in one year or less ​ ​ ​ $ 515,364 ​ $ 513,652 Due after one year through five years ​ ​ ​ 270,591 ​ 263,105 Due after five years through ten years ​ ​ ​ ​ — ​ ​ — Due after ten years ​ ​ ​ 3,070 ​ 3,070 Total marketable securities ​ ​ ​ $ 789,025 ​ $ 779,827 ​ Expected maturities could differ from contractual maturities because the security issuers may have the right to prepay obligations without prepayment penalties. The Company reviews the marketable securities for impairment at each reporting period to determine if any of the securities have experienced an other-than-temporary decline in fair value. The Company considers factors, such as the length of time and extent to which the market value has been less than the cost, the financial condition and near-term prospects of the issuer, the Company’s intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of its amortized cost basis. If the Company believes that an other-than-temporary decline in fair value has occurred, it writes down the investment to its fair value and recognizes the credit loss in earnings and the non-credit loss in accumulated other comprehensive income or loss. Unrealized losses from fixed-income securities are primarily attributable to changes in interest rates. Management does not believe any unrealized losses represent impairments based on our evaluation of the available evidence.

Acquisitions

Acquisitions	6 Months Ended
	Mar. 31, 2023
Business Combinations [Abstract]
Acquisitions	5. Business Combinations The Company recorded the assets acquired and liabilities assumed related to the following acquisitions at their fair values as of the acquisition date, from a market participant’s perspective. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed on the acquisition date, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company’s results of operations. The finalization of the assignment of fair values will be completed within one year after the respective acquisition date. Acquisitions Completed in Fiscal Year 2023 ​ Ziath Ltd ​ On February 2, 2023 , the Company acquired Ziath Ltd and its subsidiaries (‘Ziath’). Based in Cambridge, United Kingdom, Ziath is a leading provider of 2D barcode readers for life sciences applications. Founded in 2005, Ziath’s innovative 2D barcode readers are a key component of the laboratory automation workflow serving pharmaceutical, biotech and academic customers worldwide. Ziath will enhance the Company’s offerings which support the entire lifecycle of sample management – from specimen collection to sample registration, storage and processing. The acquisition was completed for a purchase price of ​ The preliminary allocation of the consideration included $12 million of goodwill, $4.1 million of technology, $1.1 million of deferred tax liability, $0.6 million of customer relationships, $0.3 million of trademarks, and several other assets and liabilities. The weighted average life of completed technology is 10 years, customer relationships is 13 years, and trademarks is 13 years. The goodwill represents the Company’s ability to provide a differentiated technology enabling high-throughput scanning of varied formats of consumables. The goodwill is not expected to be deductible for income tax purposes. ​ The Company did not present a pro forma information summary for its consolidated results of operations for the acquisitions because such results were immaterial. ​ B Medical Systems S.á r.l. ​ On October 3, 2022, the Company acquired B Medical Systems S.á r.l. and its subsidiaries ("B Medical"), for a purchase price of approximately $432.2 million including contingent consideration, which the Company estimated the fair value to be $17 million as of the measurement date. B Medical is a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments to more than 150 countries worldwide. B Medical’s results of operations are reported in the Company’s Life Sciences Products reportable segment from the date of acquisition. The Company paid a total initial cash purchase price at closing of $424 million, as adjusted for cash acquired and other items pursuant to the acquisition agreement. B Medical Systems Holdings S.A (the “Seller”) is eligible to earn up to approximately €50 million in contingent consideration based upon achievement of certain financial metrics by B Medical and its subsidiaries. Included in the purchase price, the Company repaid B Medical’s outstanding debt of $43.1 million prior to September 30, 2022 which was classified in prepaid assets as of September 30, 2022. In addition, as of September 30, 2022, the Company had recorded $381 million in short-term restricted cash, which was reserved to complete the acquisition on October 3, 2022. The contingent consideration payment is based on achievement of certain revenue targets over the one-year period from October 3, 2022 to September 30, 2023. Pursuant to ASC 805, Business Combinations (“ASC 805”), the Company recorded its estimate of the fair value of the contingent consideration liability utilizing the Monte Carlo simulation based on future revenue projections, revenue growth rates of comparable companies, implied volatility and applying a risk adjusted discount rate. Each quarter, the Company is required to remeasure the fair value of this liability as assumptions change over time and any resulting adjustments in the fair value of this liability are recorded in “Operating expenses” in the Company’s Consolidated Statements of Operations. This fair value measurement was based on significant inputs not observable in the market and thus represented a Level 3 measurement as defined in ASC 820. This fair value measurement is directly impacted by the Company’s estimate of future incremental revenue growth of the business. Accordingly, if actual revenue growth is higher or lower than the estimates within the fair value measurement, the Company would record additional charges or gains. As of March 31, 2023, the contingent consideration liability was The total purchase price was allocated to B Medical’s tangible and identifiable intangible assets and liabilities based on the estimated fair values as of October 3, 2022, as set forth below: ​ ​ ​ ​ ​ ​ Fair Value of ​ ​ Assets and ​ ​ Liabilities Accounts receivable ​ ​ 19,549 Inventory ​ 49,497 Other assets ​ 10,769 Property plant and equipment ​ 54,149 Identifiable Intangible Assets: ​ ​ Completed technology ​ 100,600 Trademarks ​ 5,500 Customer relationships ​ 36,700 Backlog ​ 600 Other liabilities ​ (31,080) Deferred income taxes, net ​ ​ (42,974) Goodwill ​ ​ 228,851 Total purchase price, net of cash acquired ​ $ 432,160 ​ During the three months ended March 31, 2023, the purchase price, net of cash acquired, remains the same. The Company recorded adjustments which resulted in a net increase to goodwill of $9.8 million. These adjustments include a $1.0 million decrease to property, plant and equipment, a $0.4 million increase to intangible assets, a $9.6 million decrease to other assets, a $0.2 million decrease to inventory and a $0.6 increase in deferred revenue. In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of B Medical’s business. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities. As part of the purchase price allocations, the Company determined the identifiable intangible assets were completed technology, trademarks, customer relationships and backlog. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a rate. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked with references to the implied rate of return from the transaction and the weighted average cost of capital. The weighted average life of completed technology is . The intangible assets acquired are amortized over their respective weighted average life using methods that approximate the pattern in which the economic benefits are expected to be realized. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Goodwill of t expected to be deductible for income tax purposes. The revenues from B Medical included in the Company's consolidated results for the three and six months ended March 31, 2023 were $15.1 million and $57.3 million, respectively. The net loss from B Medical included in the Company's consolidated results for the three and six months ended March 31, 2023 were $10.4 million and $13.0 million, respectively. The Company incurred $8.9 million in transaction costs related to the acquisition of which $0.2 million was incurred during the three months ended March 31, 2023. The following unaudited pro forma information reflects our consolidated results of operations as if the acquisition had taken place on October 1, 2021. The unaudited pro forma information is not necessarily indicative of the results of operations that we would have reported had the transaction actually occurred at the beginning of these periods nor is it necessarily indicative of future results. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended, March 31, ​ ​ ​ ​ Six Months Ended, March 31, ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenue ​ $ 148,401 ​ $ ​ 178,812 ​ ​ ​ $ 326,767 ​ ​ $ 357,433 ​ Net (loss) income ​ ​ (3,233) ​ $ ​ 2,117,936 ​ ​ ​ ​ (9,078) ​ ​ ​ 2,150,720 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ To present our consolidated results of operations as if the acquisition had taken place on October 1, 2021, the unaudited pro forma earnings for the three months and six months ended March 31, 2022 have been adjusted to include the following additional expenses related o the acquisition: $6.4 million and $12.7 million, respectively, of property, plant and equipment, inventory, and intangible asset step-up depreciation and amortization expense. Non-recurring acquisition related items and significant GAAP adjustments included in the three months and six months ended March 31, 2022 include $8.7 million and $8.9 million, respectively, of transactions costs, $5.4 million and $5.7 million of reversal of debt interest expense, and $1.4 million and $1.6 million expensed as a reversal of research and development capitalization. The unaudited pro forma earnings for the three months and six months ended March 31, 2023 have been adjusted to include the following additional expenses related to the acquisition: $2.7 million and $5.4 million, respectively, of property, plant and equipment, inventory, and intangible asset step-up depreciation and amortization expense and non-recurring acquisition of $0.3 million and $4.9 million related to transaction costs. The pro forma information does not include any anticipated cost savings or other effects of the integration of B Medical. Accordingly, the unaudited pro forma information does not necessarily reflect the actual results that would have occurred, nor is it necessarily indicative of future results of operations ​ Acquisition Completed in Fiscal Year 2022 ​ Barkey Holding GmbH ​ On July 1, 2022, the Company acquired Barkey Holding GmbH and its subsidiaries (“Barkey”), a leading provider of controlled-rate thawing devices for customers in the medical, biotech and pharmaceutical industries, head quartered in Leopoldshöhe, Germany. The Company has included the financial results of the acquired operations within the Life Sciences Products segment. The total cash purchase price of the acquisition was approximately $84.8 million, net of cash acquired. The acquisition brings innovative products and capabilities that extend the Company’s extensive cold chain of condition portfolio of products and services, while also expanding our customer reach in the fast-growing cell and gene therapy space. The allocation of the consideration included $3.0 million of customer relationships, $29.0 million of technology, $57.8 million of goodwill, $9.8 million of deferred tax liabilities, and several other assets and liabilities. The weighted useful life of all the intangible assets acquired is 15 years. The goodwill and intangibles are not tax deductible. The Company did not present a pro forma information summary for its consolidated results of operations for the acquisitions completed in fiscal year 2022 because such results were immaterial.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	6. Goodwill and Intangible Assets Goodwill represents the excess of purchase price over the fair value of net tangible and identifiable intangible assets of the businesses acquired by the Company. Goodwill is tested for impairment annually or more often if impairment indicators are present at the reporting unit level. The Company has elected April 1 st reporting units are below their carrying values, the Company performs additional impairment tests during interim periods to evaluate goodwill for impairment. Application of the goodwill impairment test requires significant judgment based on market and operational conditions at the time of the evaluation, including management’s best estimate of future business activity and the related estimates of future cash flows from the assets and the reporting units that include the associated goodwill. These periodic evaluations could cause management to conclude that impairment factors exist, requiring an adjustment of these assets to their then current fair market values. Future business conditions and/or activity could differ materially from the projections made by management which could result in impairment charges. The goodwill impairment test is performed at the reporting unit level. A reporting unit is either an operating segment or one level below it, which is referred to as a “component”. The level at which the impairment test is performed requires an assessment of whether the operations below an operating segment constitute a self-sustaining business, in which case testing is generally performed at this level. In accordance with ASC 350, Intangibles-Goodwill and Other , the Company first assesses qualitative factors to determine whether the existence of events or circumstances indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying value. If the Company determines, based on this assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying value, it performs a quantitative goodwill impairment test by comparing the reporting unit’s fair value with its carrying value. An impairment loss is recognized for the amount by which the reporting unit’s carrying value exceeds its fair value, up to the total amount of goodwill allocated to the reporting unit. We determine fair values of our reporting units based on an income approach in accordance with the discounted cash flow method, or DCF Method. The DCF Method is based on projected future cash flows and terminal value estimates discounted to their present values. Terminal value represents the present value an investor would pay on the valuation date for the rights to the cash flows of the business for the years subsequent to the discrete cash flow projection period. We consider the DCF Method to be the most appropriate valuation technique since it is based on management’s long-term financial projections. In addition to determining the fair value of our reporting units based on the DCF Method, we also compare the aggregate values of our net corporate assets and reporting unit fair values to our overall market capitalization and use certain market-based valuation techniques to assess the reasonableness of the reporting unit fair values determined in accordance with the DCF Method. The key inputs used in the DCF Method include revenue growth rates, gross margin percentage, selling, general and administrative expense percentage and discount rates that are at or above our weighted average cost of capital. We derive discount rates that are commensurate with the risks and uncertainties inherent in the respective reporting units and our internally developed projections of future cash flows. Application of the goodwill impairment test requires judgment based on market and operational conditions at the time of the evaluation, including management’s best estimates of the reporting unit’s future business activity and the related estimates and assumptions of future cash flows from the assets that include the associated goodwill. Different assumptions of revenue growth rates, gross margin percentage, selling, general and administrative expense percentage and the discount rate used in the DCF Method could result in different estimates of the reporting unit’s fair value as of each testing date. In the second quarter of 2023, as part of the Company’s routine long-term planning process, the Company assessed several events and circumstances that could affect the significant inputs used to determine the fair value of its reporting units, including updates to forecasted margins and cash flows, and the overall change in the economic climate since our last impairment assessment. The Company considered the impairment indicators as described in ASC 350 and determined it appropriate to perform a quantitative assessment of both its reporting units as of March 31, 2023. The estimated fair value of the Life Sciences Services and Life Sciences Products reporting units exceeded their respective carrying values by approximately In the event the financial performance of either of the reporting units does not meet our expectations in the future, we experience a prolonged macroeconomic or market downturn, declines in our stock price, or there are other negative revisions to key assumptions used in our DCF Method, we may be required to perform additional impairment analyses and could be required to recognize an impairment charge. Please refer to Note 8, "Goodwill and Intangible Assets" to the Company's consolidated financial statements included in the 2022 Annual Report on Form 10-K for further information on the goodwill impairment testing performed during fiscal year 2022. The changes in the Company’s goodwill by reportable segment for the six months ended March 31, 2023 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences ​ Life Sciences ​ ​ ​ ​ ​ Products ​ Services ​ Total Balance, at September 30, 2022 ​ $ 154,612 ​ $ 359,011 ​ $ 513,623 Acquisitions ​ 228,851 ​ — ​ 228,851 Currency translation adjustments ​ ​ 47,998 ​ ​ 22 ​ ​ 48,020 Balance, at March 31, 2023 ​ $ 431,461 ​ $ 359,033 ​ $ 790,494 ​ During the six months ended March 31, 2023, the Company recorded goodwill related to the B Medical and Ziath acquisitions of $228.9 million and an increase in goodwill of $48.0 million related to foreign currency translation adjustments. ​ The components of the Company’s identifiable intangible assets as of March 31, 2023 and September 30, 2022 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2023 ​ September 30, 2022 ​ ​ ​ ​ Accumulated ​ Net Book ​ ​ ​ Accumulated ​ Net Book ​ Cost Amortization Value Cost Amortization Value Patents ​ $ 8,996 ​ $ 8,911 ​ $ 85 ​ $ 1,225 ​ $ 1,106 ​ $ 119 Completed technology ​ 258,146 ​ 85,726 ​ 172,420 ​ 99,525 ​ 37,991 ​ 61,534 Trademarks and trade names ​ 8,848 ​ 2,865 ​ 5,983 ​ 400 ​ 41 ​ 359 Non-competition agreements ​ ​ 731 ​ ​ 553 ​ ​ 178 ​ ​ 681 ​ ​ 439 ​ ​ 242 Customer relationships ​ 321,024 ​ 176,432 ​ 144,592 ​ 246,949 ​ 130,802 ​ 116,147 Other intangibles ​ ​ 896 ​ ​ 227 ​ ​ 669 ​ ​ 202 ​ ​ 202 ​ ​ — ​ ​ $ 598,641 ​ $ 274,714 ​ $ 323,927 ​ $ 348,982 ​ $ 170,581 ​ $ 178,401 ​ During the six months ended March 31, 2023, the Company recorded intangible assets related to the B Medical and Ziath acquisitions of ​ Amortization expense for intangible assets was $12.4 million and $7.9 million, respectively, for the three months ended March 31, 2023 and 2022. Amortization expense for intangible assets was $24.0 million and $15.9 million, for the six months ended March 31, 2023 and 2022, respectively. ​ Estimated future amortization expense for the intangible assets for the remainder of fiscal year 2023, the subsequent four fiscal years and thereafter is as follows (in thousands): ​ ​ ​ ​ 2023 ​ $ 24,217 2024 ​ 50,542 2025 ​ 49,151 2026 ​ 45,754 2027 ​ ​ 37,573 Thereafter ​ ​ 116,690 Total ​ $ 323,927

Leases

Leases	6 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Leases	7. Leases The Company has operating leases for real estate and non-real estate and finance leases for non-real estate in North America, Europe, and Asia. Non-real estate leases are primarily related to vehicles and office equipment. Lease expiration dates range between 2023 and 2042. The components of lease expense were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease costs ​ ​ ​ $ 3,086 ​ $ 2,389 ​ $ 6,150 ​ $ 4,560 ​ Finance lease costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of assets ​ ​ ​ ​ 151 ​ ​ 54 ​ ​ 242 ​ ​ 129 ​ Interest on lease liabilities ​ ​ ​ ​ 9 ​ ​ 2 ​ ​ 13 ​ ​ 5 ​ Total finance lease costs ​ ​ ​ ​ 160 ​ ​ 56 ​ ​ 255 ​ ​ 134 ​ Variable lease costs ​ ​ ​ ​ - ​ ​ 755 ​ ​ 2 ​ ​ 1,272 ​ Short-term lease costs ​ ​ ​ ​ 226 ​ ​ 364 ​ ​ 410 ​ ​ 718 ​ Sublease income ​ ​ ​ ​ (2) ​ ​ - ​ ​ (4) ​ ​ - ​ Total lease costs ​ ​ ​ $ 3,470 ​ $ 3,564 ​ $ 6,813 ​ $ 6,684 ​ ​ Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2023 ​ September 30, 2022 ​ Operating Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 63,122 ​ $ 54,059 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 8,778 ​ $ 6,924 ​ Long-term operating lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 57,137 ​ ​ 49,227 ​ Total operating lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 65,915 ​ $ 56,151 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Property, plant and equipment, at cost ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 4,010 ​ $ 2,476 ​ Accumulated amortization ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (2,504) ​ ​ (2,276) ​ Property, plant and equipment, net ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 1,506 ​ $ 200 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 543 ​ $ 96 ​ Other long-term liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1,129 ​ ​ 98 ​ Total finance lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 1,672 ​ $ 194 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining lease term (in years): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 10.10 ​ ​ 10.82 ​ Finance leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 3.46 ​ ​ 2.19 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average discount rate: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 4.04 % ​ 3.93 % Finance leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2.44 % ​ 1.29 % ​ Supplemental cash flow information related to leases was as follows (in thousands, unaudited): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ Cash paid for amounts included in measurement of liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ ​ ​ $ 2,631 ​ $ 1950 ​ $ 5,200 ​ $ 3,599 ​ Operating cash flows from finance leases ​ ​ ​ ​ 9 ​ ​ 1 ​ ​ 13 ​ ​ 4 ​ Financing cash flows from finance leases ​ ​ ​ ​ 139 ​ ​ 127 ​ ​ 226 ​ ​ 312 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ROU assets obtained in exchange for lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ $ 7,230 ​ $ 7,327 ​ $ 6,464 ​ $ 7,490 ​ Finance leases ​ ​ ​ ​ 270 ​ ​ - ​ ​ 1,060 ​ ​ - ​ ​ ​ Future lease payments for operating and finance leases as of March 31, 2023 were as follows for the remainder of fiscal year 2023, the subsequent four fiscal years and thereafter (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases Operating Leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 298 ​ $ 5,779 ​ 2024 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 540 ​ ​ 10,613 ​ 2025 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 450 ​ ​ 10,316 ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 308 ​ ​ 7,974 ​ 2027 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 135 ​ ​ 7,552 ​ Thereafter ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 17 ​ ​ 39,860 ​ Total future lease payments ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1,748 ​ ​ 82,094 ​ Less imputed interest ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (76) ​ ​ (16,179) ​ Total lease liability balance ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 1,672 ​ $ 65,915 ​ As of March 31, 2023, the Company did not have significant leases that have not commenced or not recorded in the accompanying unaudited Consolidated Balance Sheets .

Income Taxes

Income Taxes	6 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes The Company recorded an income tax benefit of $3.3 million and $7.9 million, respectively during the three and six months ended March 31, 2023. The tax benefit for the three months ended March 31, 2023 was primarily driven by the pre-tax loss from operations during the period. The tax benefit for the six months ended March 31, 2023 was primarily driven by the pre-tax loss from operations and a $1.4 million deferred tax benefit resulting from the extension of a tax incentive in China. The effective tax rates for the three and six months ended March 31, 2023 are substantially higher than statutory rates. The effective rates are driven higher than statutory rates by the discrete tax benefit in China noted above and the fair value adjustment of the contingent consideration related to the B Medical acquisition. The contingent consideration generated $17.1 million of pre-tax income that is not subject to income taxes, therefore, the tax benefit is being driven by a tax loss that is significantly higher than the book loss for these periods. The effective tax rate on a six-month basis without these discrete events is slightly higher than average statutory tax rates due to the jurisdictional mix of income with losses being generated in higher tax jurisdictions and income being generated in lower jurisdictions. ​ The Company recorded an income tax benefit of $3.2 million and $7.9 million, respectively, during the three and six months ended March 31, 2022. The tax benefit for the three months ended March 31, 2022 was primarily driven by the benefit on loss from operations during the period. The tax benefit for the six months ended March 31, 2022 was increased by a $4.5 million discrete stock compensation windfall benefit for tax deductions that exceeded the associated book compensation expense. The tax benefit for the six months ended March 31, 2022 was partially offset by a $0.6 million charge to increase the deferred tax liability to reflect a change in the blended state income tax rate that results from the sale of the semiconductor business assets. The effective tax rates for the three and six months ended March 31, 2022 were significantly higher than the statutory rates. The higher effective rates were driven by the tax benefit on the stock compensation deduction and near break-even pre-tax losses of $1.8 million and $5.0 million, respectively, in the 2023 periods. ​ The in the course of The Company maintains liabilities for unrecognized tax benefits. These liabilities involve judgment and estimation, and they are monitored based on the best information available. The Company recognizes interest related to unrecognized tax benefits as unrecognized benefits The In on those benefits will be reduced by in the next twelve months ​

Other Balance Sheet Information

Other Balance Sheet Information	6 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Balance Sheet Information	9. Other Balance Sheet Information The following is a summary of accounts receivable at March 31, 2023 and September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ September 30, ​ ​ 2023 2022 Accounts receivable ​ $ 175,656 ​ $ 168,920 ​ Less allowance for expected credit losses ​ (7,696) ​ (5,162) ​ Accounts receivable, net ​ $ 167,960 ​ $ 163,758 ​ ​ ​ The allowance for expected credit losses for the six months ended March 31, 2023 and fiscal year ended September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at ​ ​ ​ ​ Reversals of ​ Write- ​ Balance at ​ ​ Beginning of ​ ​ ​ ​ Bad Debt ​ offs and ​ End of Description Period Provisions Expense Adjustments Period Six months ended March 31, 2023 allowance for expected credit losses ​ $ 5,162 ​ ​ 4,858 ​ ​ (2,254) ​ $ (70) ​ $ 7,696 Fiscal year 2022 allowance for expected credit losses ​ 4,318 ​ ​ 3,020 ​ ​ (2,510) ​ $ (414) ​ ​ 4,414 ​ The following is a summary of inventories at March 31, 2023 and September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, September 30, ​ ​ 2023 2022 Inventories ​ Raw materials and purchased parts $ 71,912 $ 39,685 ​ Work-in-process ​ 5,065 ​ 4,816 ​ Finished goods ​ 73,750 ​ 41,043 ​ Total inventories $ 150,727 $ 85,544 ​ ​ ​ Reserves related to write downs or adjustments of inventory to net realizable value were $4.1 million and $4.1 million, respectively, at March 31, 2023 and September 30, 2022. At March 31, 2023 and September 30, 2022, the Company had cumulative capitalized direct costs of $28.7 million and $26.9 million, respectively, associated with the development of software for its internal use. As of March 31, 2023, this balance included $10.2 million associated with software assets that are still in the development stage and not yet placed in service. During the three and six months ended March 31, 2023, the Company capitalized direct costs associated with the development of software for its internal use of $0.7 million and $1.8 million, respectively, as compared to $0.8 million and $1.3 million, respectively, during the corresponding period of the prior fiscal year. The Company establishes reserves for estimated costs of product warranties based on historical information. Product warranty reserves are recorded at the time product revenue is recognized, and retrofit accruals are recorded at the time retrofit programs are established. The Company’s warranty obligation is affected by product failure rates, utilization levels, material usage, service delivery costs incurred in correcting a product failure and supplier warranties on parts delivered to the Company. The following is a summary of product warranty and retrofit activity on a gross basis for the three and six months ended March 31, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Three Months Ended March 31, 2023 Balance ​ ​ ​ ​ ​ ​ ​ Balance December 31, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ ​ Adjustments for Acquisitions ​ Accruals ​ Costs Incurred ​ 2023 $ 5,179 ​ ​ — ​ $ 1,222 ​ $ (1,021) ​ $ 5,380 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Three Months Ended March 31, 2022 Balance ​ ​ ​ ​ ​ ​ ​ Balance December 31, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2021 ​ ​ Adjustments for Acquisitions ​ Accruals ​ Costs Incurred ​ 2022 $ 2,342 ​ ​ — ​ $ 539 ​ $ (390) ​ $ 2,491 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Six Months Ended March 31, 2023 Balance ​ ​ ​ ​ ​ ​ ​ Balance September 30, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ ​ Adjustments for Acquisitions ​ Accruals ​ Costs Incurred ​ 2023 $ 2,890 ​ ​ 2,303 ​ $ 1,529 ​ $ (1,342) ​ $ 5,380 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Six Months Ended March 31, 2022 Balance ​ ​ ​ ​ ​ ​ ​ Balance September 30, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2021 ​ ​ Adjustments for Acquisitions ​ Accruals ​ Costs Incurred ​ 2022 $ 2,330 ​ ​ — ​ $ 1,212 ​ $ (1,051) ​ $ 2,491

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Mar. 31, 2023
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	10. Stock-Based Compensation The Company may issue to eligible employees options to purchase shares of the Company’s stock, restricted stock and other equity incentives which vest upon the satisfaction of a performance condition and/or a service condition. In addition, the Company issues shares to participating employees pursuant to an employee stock purchase plan, and stock awards and deferred restricted stock units to its directors in accordance with its director compensation program. The stock-based compensation expense for restricted stock units for continuing operations was $3.9 million and $5.2 million, for the three months ended March 31, 2023 and 2022, respectively. The stock-based compensation expense for restricted stock units for continuing operations was $5.8 million and $7.7 million for the six months ended March 31, 2023 and 2022, respectively. The stock-based compensation expense for employee stock purchase plan for continuing operations was $0.4 million and $0.4 million, respectively, for the three months ended March 31, 2023 and 2022. The stock-based compensation expense for employee stock purchase plan for continuing operations was $0.7 million and $0.8 million, respectively, for the six months ended March 31, 2023 and 2022. The information included within the remaining note is on a total company basis, and includes amounts related to our discontinued operations. The following table reflects the total stock-based compensation expense recorded during the three and six months ended March 31, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ 2023 2022 2023 2022 Restricted stock units ​ $ 3,634 ​ $ 8,058 ​ $ 5,393 ​ $ 15,255 ​ Employee stock purchase plan ​ 356 ​ 599 ​ 703 ​ 1,293 ​ Total stock-based compensation expense ​ $ 3,990 ​ $ 8,657 ​ $ 6,096 ​ $ 16,548 ​ ​ The fair value of restricted stock units is determined based on the number of shares granted and the closing price of the Company’s common stock quoted on the Nasdaq Stock Market on the date of grant. For awards that vest based on service conditions, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period. For awards that vest subject to performance conditions, the Company recognizes stock-based compensation expense ratably over the performance period if it is probable that performance condition will be met and adjusted for the probability percentage of achieving the performance goals. The Company makes estimates of stock award forfeitures and the number of awards expected to vest. The Company considers many factors in developing forfeiture estimates, including award types, employee classes and historical experience. Each quarter, the Company assesses the probability of achieving the performance goals. Current estimates may differ from actual results and future changes in estimates. The Company grants restricted stock units that vest over a required service period and/or achievement of certain operating performance goals. Restricted stock units granted with performance goals may also have a required service period following the achievement of all or a portion of the performance goals. The following table reflects restricted stock units and stock awards granted during the six months ended March 31, 2023 and 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Time-Based Stock Performance- ​ ​ Total Units ​ Units ​ Grants ​ Based Units Six months ended March 31, 2023 572,111 356,410 — 215,701 Six months ended March 31, 2022 228,468 ​ 101,706 16,286 110,476 ​ Time-Based Restricted Stock Unit Grants Restricted stock units granted with a required service period typically have three-year vesting schedules in which one-third one-third one-third Stock-Based Awards – Board of Directors The stock-based awards granted to the members of the Company’s Board of Directors include stock awards, restricted stock awards, deferred stock and restricted stock units. Certain members of the Board of Directors have elected to defer receiving their annual stock awards and related quarterly dividends, if any, until they attain a certain age or cease to provide services as a member of the Company’s Board of Directors. Annual deferred restricted stock units granted during fiscal years 2023 and 2022 were vested upon issuance. Performance-Based Restricted Stock Unit Grants Performance-based restricted stock units are earned based on the achievement of performance criteria established by the Human Resources and Compensation Committee and approved by the Board of Directors. The criteria for performance-based awards are weighted and have threshold, target and maximum performance goals. Performance-based awards granted in fiscal year 2023, 2022 and 2021 allow participants to earn 100% of the restricted stock units if the Company’s performance meets or exceeds its target goal for each applicable financial metric, and up to a maximum of 200% if the Company’s performance for such metrics meets or exceeds the maximum or stretch goal. Performance below the minimum threshold for each financial metric results in award forfeiture. Performance goals will be measured over a three-year period for each year’s awards and at the end of the period to determine the number of units earned by recipients who continue to meet the service requirement. Around the third anniversary of each year’s awards’ grant date, the Company’s Board of Directors determines the number of units earned for participants who continue to meet the service requirements on the vest date. Restricted Stock Unit Activity The following table summarizes restricted stock unit activity for the six months ended March 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ ​ Grant-Date ​ ​ Shares ​ Fair Value Outstanding at September 30, 2022 538,238 ​ $ 71.99 Granted 572,111 ​ ​ 58.21 Vested (261,618) ​ ​ 55.66 Forfeited (81,878) ​ ​ 78.66 Outstanding at March 31, 2023 766,853 ​ ​ 67.68 ​ The weighted average grant date fair value of restricted stock units granted during the three months ended March 31, 2023 and 2022 was $58.21 and $82.34, respectively. The fair value of restricted stock units vested during the three months ended March 31, 2023 and 2022 was $2.6 million and $1.9 million, respectively. During the six months ended March 31, 2023 and 2022, the Company remitted $4.9 million and $25.1 million, respectively, to satisfy employee tax obligations as a result of share issuances, of which $4.9 million and $0, respectively, was paid by the Company. During the three months ended March 31, 2023 and 2022, the Company remitted $0 million and $0 million, respectively, from employees to satisfy their tax obligations as a result of share issuances. As of March 31, 2023, the unrecognized compensation cost that are expected to vest is $31.1 million and will be recognized over an estimated weighted average service period of approximately 2.04 years. Employee Stock Purchase Plan The Company maintains an employee stock purchase plan that allows its employees to purchase shares of common stock at a price equal to 85% of the fair market value of the Company’s stock at the beginning or the end of the semi-annual offering period, whichever is lower. There were 39,479 and 51,133 shares, respectively, purchased by employees under the employee stock purchase plan during the six months ended March 31, 2023 and 2022.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Stockholders' Equity	11. Stockholders’ Equity On November 4, 2022, the Company’s Board of Directors terminated ​ On November 23, 2022, the Company executed an Accelerated Share Repurchase Agreement (the “ASR Agreement”) with JPMorgan Chase Bank, National Association (the “Dealer”) to repurchase an aggregate of up to $500.0 million of the Company’s common stock . Under the terms of the ASR Agreement, the Company made a payment of Derivatives and Hedging , and concluded equity classification was appropriate. The shares of common stock repurchased by the Company under the ASR Agreement were retired, accounted for as a reduction to stockholders’ equity in the Company’s Consolidated Balance Sheets and treated as a repurchase of common stock for purposes of calculating earnings per share as of the applicable settlement date. As of March 31, 2023, after giving effect to the ASR Agreement, approximately $1.0 billion of the amount authorized remained available for additional repurchases of the Company’s common stock. Following the final termination of the ASR Agreement in April 2023, new arrangements commenced under which the Company expects to repurchase up to an additional $500 million shares of common stock in open market purchases, subject to market and business conditions, legal requirements, and other factors.

Earnings per Share

Earnings per Share	6 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Earnings per Share	12. Earnings per Share The calculations of basic and diluted net income (loss) per share and basic and diluted weighted average shares outstanding are as follows for the three and six months ended March 31, 2023 and 2022 (in thousands, except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ March 31, ​ March 31, ​ ​ 2023 2022 2023 2022 Income (loss) from continuing operations ​ $ (1,991) ​ $ (1,816) ​ $ (13,226) ​ $ 1,041 ​ Income (loss) from discontinued operations, net of tax ​ (2,936) ​ 2,121,690 ​ (2,936) ​ 2,162,152 ​ Net income (loss) ​ $ (4,927) ​ $ 2,119,874 ​ $ (16,162) ​ $ 2,163,193 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used in computing basic income (loss) per share ​ 69,111 ​ 74,958 ​ 70,858 ​ 74,823 ​ Dilutive restricted stock units ​ — ​ — ​ — ​ 322 ​ Weighted average common shares outstanding used in computing diluted income (loss) per share ​ 69,111 ​ 74,958 ​ 70,858 ​ 75,145 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic net income (loss) per share: ​ ​ ​ ​ ​ Income (loss) from continuing operations ​ $ (0.03) ​ $ (0.02) ​ $ (0.19) ​ $ 0.01 ​ Income (loss) from discontinued operations, net of tax ​ (0.04) ​ 28.31 ​ (0.04) ​ 28.90 ​ Basic net income (loss) per share ​ $ (0.07) ​ $ 28.28 ​ $ (0.23) ​ $ 28.91 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diluted net income (loss) per share: ​ ​ ​ ​ ​ Income (loss) from continuing operations ​ $ (0.03) ​ $ (0.02) ​ $ (0.19) ​ $ 0.01 ​ Income (loss) from discontinued operations, net of tax ​ (0.04) ​ 28.31 ​ (0.04) ​ 28.77 ​ Diluted net income (loss) per share ​ $ (0.07) ​ $ 28.28 ​ $ (0.23) ​ $ 28.79 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ During the six months ended March 31, 2022, 59,513 restricted stock units were excluded from the computation of diluted loss per share as their effect would be antidilutive to earnings per share for continuing operations based on the treasury stock method.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	6 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	13. Revenue from Contracts with Customers Disaggregated Revenue The Company disaggregates revenue from contracts with customers in a manner that depicts how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The following is revenue by significant business line for the three and six months ended March 31, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ ​ Six months ended March 31, ​ ​ ​ ​ 2023 ​ ​ 2022 ​ ​ ​ 2023 ​ 2022 Significant Business Line ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products, excluding B Medical ​ ​ ​ $ 43,738 ​ ​ $ 53,615 ​ ​ $ 91,576 ​ $ 103,493 B Medical ​ ​ ​ ​ 15,122 ​ ​ ​ - ​ ​ ​ 56,944 ​ ​ - Sample Repository Solutions ​ ​ ​ ​ 27,305 ​ ​ ​ 26,929 ​ ​ ​ 54,921 ​ ​ 52,805 Genomic Services ​ ​ ​ ​ 62,236 ​ ​ ​ 65,000 ​ ​ ​ 123,326 ​ ​ 128,898 Total ​ ​ ​ $ 148,401 ​ ​ $ 145,544 ​ ​ $ 326,767 ​ $ 285,196 ​ ​ Contract Balances Accounts Receivable, net allowance for expected credit losses. Contract Assets. ​ Contract Liabilities. ​ Remaining Performance Obligations. aggregate amount of transaction consideration allocated to remaining performance obligations as of March 31, 2023 was $91.5 million. The following table summarizes when the Company expects to recognize the remaining performance obligations as revenue; the Company will recognize revenue associated with these performance obligations as transfer of control occurs (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2023 ​ ​ Less than 1 Year ​ Greater than 1 Year ​ Total Remaining Performance Obligations ​ $ 58,944 ​ $ 32,516 ​ $ 91,460 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cost to Obtain and Fulfill a Contract The Company capitalizes sales commissions when incurred if they are (i) incremental costs of obtaining a contract, (ii) expected to be recovered and (iii) have an expected amortization period that is greater than one year. As part of the Company’s cumulative effect adjustment upon the initial adoption of ASC 606, incremental costs associated with obtaining a contract were capitalized and have been classified as deferred commissions within the Company’s Consolidated Balance Sheet. These amounts primarily relate to sales commissions and are being amortized over a 60-month period, which represents the average period of contract performance. The Company did not capitalize any sales commissions during the six months ended March 31, 2023 and 2022 as the amount of sales commissions that qualified for capitalization during the reporting period was insignificant. Sales commissions incurred during the reporting period have been expensed as incurred. These costs are recorded within “Selling, general and administrative” expenses on the Company’s Consolidated Statement of Operations. The Company has concluded that none of its costs incurred in fulfillment of customer contracts meet the capitalization criteria. The Company will account for shipping and handling activities as fulfillment activities and recognize the associated expense when control of the product has transferred to the customer.

Segment and Geographic Informat

Segment and Geographic Information	6 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segment and Geographic Information	14. Segment and Geographic Information Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and to assess performance. The Company’s Chief Executive Officer is the Company’s chief operating decision maker. The Company operates in two reportable segments: the Life Sciences Products segment and the Life Sciences Services segment. These reportable segments also represent the Company’s operating segments. The Company previously operated in reportable segments: the Semiconductor Solutions Group segment, the Life Sciences Products segment, and the Life Sciences Services segment. The Company’s Life Sciences Products segment provides automated cold storage solutions for biological and chemical compound samples. The Company’s storage systems provide reliable automation and sample inventory management at temperatures down to -190°C and can store anywhere from one to millions of samples. The Company’s sample management solutions include consumable vials and tubes, polymerase chain reaction (PCR), plates, instruments for supporting workflows, and informatics. This portfolio provides customers with the highest level of sample quality, security, availability, intelligence, and integrity throughout the lifecycle of samples providing customers with complete end-to-end “cold-chain of custody” capabilities. The Company also provides controlled rate thawing devices for customers in the medical, biotech and pharmaceutical industries. On October 3, 2022 , the Company acquired B Medical, a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments to people in more than 150 countries worldwide. On February 2, 2023, the Company acquired Ziath a leading provider of 2D barcode readers for life sciences applications. Both of the acquired businesses are part of the Company’s Life Sciences Products segment. ​ The Company’s Life Sciences Services business is a leading provider of solutions addressing the many needs of customers in the area of genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research and development markets. The Company processes millions of samples every year, each containing valuable information that must be delivered or preserved with the sample. The Company’s genomic services provide a broad capability to customers for sequencing and synthesis of genes. The Company’s sample management services include off-site storage services, transport services, laboratory services, and interactive informatics solutions. The storage services include short- and long-term sample storage and management of the “cold chain of custody” from collection, to storage, to retrieving the sample which ultimately may go back into the research workflow. The Company considers adjusted operating income, which excludes charges related to amortization of completed technology, the purchase accounting impact on inventory, amortization of other intangible assets, restructuring related charges, contingent consideration fair value adjustments, tariff adjustment, other unallocated corporate expenses, as the primary performance metric when evaluating the business. The following is the summary of the financial information for the Company’s reportable segments for the three and six months ended March 31, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ Revenue: ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ 58,860 ​ $ 53,615 ​ $ 148,520 ​ $ 103,487 ​ Life Sciences Services ​ ​ 89,541 ​ 91,929 ​ 178,247 ​ 181,709 ​ Total revenue ​ ​ $ 148,401 ​ $ 145,544 ​ $ 326,767 ​ $ 285,196 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating income / (loss): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ (16,404) ​ $ 5,288 ​ $ (20,202) ​ $ 9,679 ​ Life Sciences Services ​ ​ (4,878) ​ 4,856 ​ (9,490) ​ 12,740 ​ Reportable segment operating income (loss) ​ ​ ​ (21,282) ​ ​ 10,144 ​ ​ (29,692) ​ ​ 22,419 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of completed technology ​ ​ ​ 4,901 ​ ​ 1,840 ​ ​ 9,070 ​ ​ 3,613 ​ Purchase accounting impact on inventory ​ ​ ​ 2,912 ​ ​ — ​ ​ 5,781 ​ ​ — ​ Amortization of other intangible assets ​ ​ ​ 7,509 ​ ​ 6,047 ​ ​ 14,882 ​ ​ 12,319 ​ Restructuring charges ​ ​ ​ 1,499 ​ ​ 122 ​ ​ 2,961 ​ ​ 295 ​ Contingent consideration - fair value adjustments ​ ​ ​ (17,145) ​ ​ — ​ ​ (17,145) ​ ​ — ​ Tariff adjustment ​ ​ ​ — ​ ​ (486) ​ ​ — ​ ​ (486) ​ Other unallocated corporate expenses ​ ​ ​ (7,981) ​ ​ 7,329 ​ ​ (4,579) ​ ​ 11,711 ​ Total operating income (loss) ​ ​ ​ (12,977) ​ ​ (4,708) ​ ​ (40,662) ​ ​ (5,033) ​ Interest income ​ ​ ​ 10,394 ​ ​ 3,076 ​ ​ 21,059 ​ ​ 3,111 ​ Interest expense ​ ​ ​ — ​ ​ (1,555) ​ ​ — ​ ​ (2,010) ​ Loss on extinguishment of debt ​ ​ ​ — ​ ​ (632) ​ ​ — ​ ​ (632) ​ Other income (expense) ​ ​ ​ (2,668) ​ ​ (1,170) ​ ​ (1,523) ​ ​ (2,248) ​ (Loss) before income taxes ​ ​ $ (5,251) ​ $ (4,989) ​ $ (21,126) ​ $ (6,812) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ Life Sciences Services ​ ​ Total ​ March 31, 2023 ​ ​ ​ ​ ​ $ 948,580 ​ $ 849,018 ​ $ 1,797,598 ​ September 30, 2022 ​ ​ ​ ​ ​ 378,790 ​ ​ 849,603 ​ 1,228,393 ​ ​ The following is a reconciliation of the Company’s reportable segments’ segment assets to the corresponding amounts presented in the accompanying unaudited Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, September 30, ​ ​ 2023 ​ 2022 Segment assets $ 1,797,598 $ 1,228,393 Cash and cash equivalents, restricted cash, and marketable securities ​ 1,451,703 ​ 2,305,081 Deferred tax assets ​ 490 ​ 1,169 Other assets ​ ​ 23 ​ ​ 181,479 Total assets ​ $ 3,249,814 ​ $ 3,716,122 ​ Revenue from external customers is attributed to geographic areas based on locations in which customer orders are placed. Net revenue by geographic area for the three and six months ended March 31, 2023 and 2022 (in thousands) are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ Six Months Ended March 31, ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ ​ Geographic Location: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ North America ​ $ 87,484 ​ $ 94,283 ​ $ 176,419 ​ $ 184,366 ​ ​ Rest of Europe ​ ​ 21,432 ​ ​ 19,745 ​ ​ 60,854 ​ ​ 40,028 ​ ​ Africa ​ ​ 8,627 ​ ​ 672 ​ ​ 25,837 ​ ​ 1,219 ​ ​ China ​ ​ 11,979 ​ ​ 13,757 ​ ​ 25,387 ​ ​ 26,798 ​ ​ Asia Pacific/ Other ​ ​ 13,090 ​ ​ 10,278 ​ ​ 27,068 ​ ​ 17,664 ​ ​ United Kingdom ​ ​ 5,789 ​ ​ 6,809 ​ ​ 11,202 ​ ​ 15,121 ​ ​ Total ​ $ 148,401 ​ $ 145,544 ​ $ 326,767 ​ $ 285,196 ​ ​ ​ Revenue for the United States comprises

Significant Customers

Significant Customers	6 Months Ended
	Mar. 31, 2023
Risks and Uncertainties [Abstract]
Significant Customers	15. Significant Customers The Company had no individual customer that accounted for 10% or more of its consolidated revenue for the three months ended March 31, 2022 and 2023. The Company had one individual customer that accounted for 10% or more of its consolidated revenue for six months ended March 31, 2023 and no significant customers that accounted for 10% or more of its consolidated revenue for the six months ended March 31, 2022. There were no customers that accounted for more than 10% of the Company’s accounts receivable balance as of March 31, 2023 and September 30, 2022.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Tariff Matter In fiscal year 2021, as part of the Company’s continued integration of GENEWIZ, which was acquired in November 2018, the Company initiated a review during the first quarter of fiscal year 2021, with the assistance of a third party consultant, of the transaction value that the Company has used to calculate tariffs on inter-company imports of samples shipped from its GENEWIZ business. As a result of the third-party review and in light of a new interpretation surrounding the valuation method used to calculate the estimated transaction value, the Company revised its estimate of the tariffs owed as a result and recorded a liability of $6.1 million in the second quarter of fiscal 2021. The Company submitted a payment in the amount of $5.9 million to the customs authorities during 2022, related to November 2021 and prior periods. The customs authorities will review the Company’s calculation of tariffs for these periods and determine if any further tariffs are owed. The Company does not expect to incur any significant penalties associated with the tariffs. Purchase Commitments At March 31, 2023, the Company had non-cancellable commitments of $83.5 million, comprised of purchase orders for inventory of $56.3 million and information technology related commitments of $27.2 million. Contingencies The Company is subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. The Company cannot predict the ultimate outcome of such legal proceedings or in certain instances provide reasonable ranges of potential losses. The Company may also have certain indemnification obligations pursuant to claims made under the definitive agreement it entered into with Edwards Vacuum LLC (a member of the Atlas Copco Group) in connection with the Company’s sale of its semiconductor cryogenics business in the fourth quarter of fiscal year 2018. However, as of the date of this report, the Company believes that none of these claims will have a material adverse effect on its consolidated financial position or results of operations. In the third quarter of fiscal year 2020, Edwards asserted claims for indemnification under the definitive agreement relating to alleged breaches of representations and warranties relating to customer warranty claims and inventory. In addition, in January 2023, Edwards filed a lawsuit against the Company in the Supreme Court of the State of New York in the County of New York seeking indemnification from the Company under such definitive agreement for approximately million, equal to the amount of the indemnification escrow as part of the loss on divestiture referred to in Note 3 “Discontinued Operations”. If the resolution of these claims results in indemnifiable losses in excess of the applicable indemnification deductibles and indemnification escrow established under the definitive agreement, Edwards would be required to seek recovery under the representation and warranty insurance Edwards obtained in connection with the closing of the transaction. The Company believes that any indemnifiable losses in excess of the applicable deductibles and indemnification escrow established in the definitive agreement would be covered by such insurance. For indemnifiable claims other than those arising from breaches of representations and warranties and for indemnifiable claims arising from breaches of representations and warranties exceeding the maximum coverage of the representations and warranties insurance policy, Edwards could seek recovery of such indemnifiable losses, if any, directly from the Company. In the event of unexpected subsequent developments and given the inherent unpredictability of these matters, there can be no assurance that the Company’s assessment of any claim will reflect the ultimate outcome, and an adverse outcome in certain matters could, from time to time, have a material adverse effect on the Company’s consolidated financial position or results of operations in particular quarterly or annual periods. ​

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	17. Fair Value Measurement The fair value measurement guidance establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following levels of inputs may be used to measure fair value: ​ Level 1 Inputs: Level 2 Inputs: Level 3 Inputs: The Company measures certain assets, including the cost and equity method investments, at fair value on a nonrecurring basis when they are deemed to be other-than-temporarily impaired. The fair values of these investments are determined based on valuation techniques using the best information available, and may include quoted market prices, market comparables, and discounted cash flow projections. An impairment charge is recorded when the cost of the investment exceeds its fair value and this condition is determined to be other-than-temporary. ​ ​ Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The following tables summarize assets and liabilities measured and recorded at fair value on a recurring basis in the accompanying Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at Reporting Date Using ​ ​ ​ Quoted Prices in ​ ​ Significant ​ ​ ​ ​ ​ Active Markets for ​ Significant Other ​ Unobservable ​ ​ March 31, ​ Identical Assets ​ Observable Inputs ​ Inputs Description ​ 2023 ​ (Level 1) ​ (Level 2) ​ (Level 3) Assets: ​ ​ ​ ​ Cash equivalents ​ $ 510,643 ​ $ 499,283 ​ $ 11,360 ​ $ — Available-for-sale securities ​ 779,827 ​ 208,527 ​ ​ 571,300 ​ — Foreign exchange contracts ​ 150 ​ — ​ 150 ​ — Net investment hedge ​ 1,278 ​ — ​ 1,278 ​ — Total assets ​ $ 1,291,898 ​ $ 707,810 ​ $ 584,088 ​ $ — Liabilities: ​ ​ ​ ​ Contingent consideration liability ​ $ 1,406 ​ $ — ​ $ — ​ $ 1,406 Foreign exchange contracts ​ ​ 164 ​ ​ — ​ ​ 164 ​ ​ — Total liabilities ​ $ 1,570 ​ $ — ​ $ 164 ​ $ 1,406 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at Reporting Date Using ​ ​ ​ Quoted Prices in ​ ​ Significant ​ ​ ​ ​ ​ Active Markets for ​ Significant Other ​ Unobservable ​ ​ September 30, ​ Identical Assets ​ Observable Inputs ​ Inputs Description ​ 2022 ​ (Level 1) ​ (Level 2) ​ (Level 3) Assets: ​ ​ ​ ​ Cash equivalents ​ $ 374,804 ​ $ 374,055 ​ $ 749 ​ $ — Available-for-sale securities ​ 1,263,782 ​ 651,800 ​ 611,982 ​ — Foreign exchange contracts ​ 634 ​ — ​ 634 ​ — Net investment hedge ​ ​ 124,789 ​ ​ — ​ ​ 124,789 ​ ​ — Total assets ​ $ 1,764,009 ​ $ 1,025,855 ​ $ 738,154 ​ $ — Liabilities: ​ ​ ​ ​ Foreign exchange contracts ​ $ 230 ​ $ — ​ $ 230 ​ $ — Total liabilities ​ $ 230 ​ $ — ​ $ 230 ​ $ — ​ Cash Equivalents Cash equivalents consist of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. The Company considers all highly liquid interest-earning investments with a maturity of three months or less at the date of purchase to be cash equivalents. The fair values of these investments approximate their carrying values. Available-For-Sale Securities Available-for-sale securities primarily consist of municipal securities and U.S. government-backed securities, and as such are classified as Level 1. Investments classified as Level 2 consist of debt securities that are valued using matrix pricing and benchmarking because they are not actively traded and bank certificate of deposits. Matrix pricing is a mathematical technique used to value securities by relying on the securities’ relationship to other benchmark quoted prices. Foreign Exchange Contracts Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy due to a lack of an active market for these contracts. Net Investment Hedge Net investment hedge assets are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy due to a lack of an active market for these contracts. Contingent Consideration Liability Contingent consideration liability related to acquisitions is measured and reported at fair value using the real options method based on the unobservable inputs that are significant to the fair value and classified with Level 3 of the fair value hierarchy. The amount is contingent based on the acquired business’ performance for a one-year period from October 3, 2022 through September 30, 2023. Please refer to Note 5, “Business Combinations” for further detail. Changes in the fair value of contingent consideration resulting from a change in the underlying inputs are recognized in results of operations until the arrangement is settled. This liability was revalued from Financial Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis During the three and six months ended March 31, 2023 and 2022, the Company did not record any material other-than-temporary impairments on financial assets required to be measured at fair value on a nonrecurring basis.

Subsequent Events

Subsequent Events	6 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	​ 18. Subsequent Event ​ As part of the $1.5 billion share repurchase authorization, the Company entered into the ASR Agreement for the repurchase of up to $500 million shares of its common stock on November 23, 2022. On April 3, 2023, the transactions under the ASR Agreement terminated, and on April 5, 2023, the Company received final settlement of an additional 4 million shares of common stock from the Dealer for a total of approximately 10 million shares of common stock repurchased under the ASR Agreement. ​ Following the final termination of the ASR Agreement in April 2023, new arrangements commenced under which the Company expect to repurchase up to an additional $500 million shares of its common stock in open market purchases, subject to market and business conditions, legal requirements, and other factors.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying Consolidated Financial Statements include the accounts of the Company and its majority-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of March 31, 2023, and its results of operations for the three months and six months ended March 31, 2023 and 2022, and cash flows for the six months ended March 31, 2023 and 2022, respectively. The consolidated balance sheet at September 30, 2022 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted and, accordingly, the accompanying financial information should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission for the fiscal year ended September 30, 2022 (the “2022 Annual Report on Form 10-K”).
Use of Estimates	Use of Estimates The preparation of unaudited consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates are associated with recording accounts receivable, inventories, goodwill, intangible assets other than goodwill, contingent consideration liabilities related to business combinations, long-lived assets, derivative financial instruments, deferred income taxes, warranty obligations, revenue over time, and stock-based compensation expense. The Company assesses the estimates on an ongoing basis and records changes in estimates in the period they occur and become known. Actual results could differ from these estimates. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, including results of operations and financial condition will depend on future developments that are highly uncertain. This includes results from new information that may emerge concerning COVID-19 and any actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within the analysis of its financial statements. ​
Business Combinations	Business Combinations The Company accounts for business acquisitions using the purchase method of accounting, in accordance with which assets acquired and liabilities assumed are recorded at their respective fair values at the acquisition date. The fair value of the consideration paid, including contingent consideration, is assigned to the assets acquired and liabilities assumed based on their respective fair values. Goodwill represents the excess of the purchase price over the estimated fair values of the assets acquired and liabilities assumed. ​ Significant judgment is used in determining fair values of assets acquired and liabilities assumed and contingent consideration, as well as intangibles and their estimated useful lives. Fair value and useful life determinations may be based on, among other factors, estimates of future expected cash flows and appropriate discount rates used in computing present values. These judgments may materially impact the estimates used in allocating acquisition date fair values to assets acquired and liabilities assumed, as well as our current and future operating results. Actual results may vary from these estimates that may result in adjustments to goodwill and acquisition date fair values of assets and liabilities during a measurement period or upon a final determination of asset and liability fair values, whichever occurs first. Adjustments to fair values of assets and liabilities made after the end of the measurement period are recorded within our operating results. ​ Changes in the fair value of contingent consideration resulting from a change in the underlying inputs are recognized in results of operations until the arrangement is settled. ​
Foreign Currency Translation	Foreign Currency Translation Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Foreign currency exchange gains (losses) generated from the settlement and remeasurement of these transactions are recognized in earnings and presented within “Other income (expenses)” in the Company’s Consolidated Statements of Operations. Net foreign currency transaction and remeasurement losses were $0.9 million and $1.2 million for the three months ended March 31, 2023 and 2022, respectively. Net foreign currency transaction and remeasurement losses were The determination of the functional currency of the Company’s subsidiaries is based on their financial and operational environment and is the local currency of the Company’s foreign subsidiaries. The subsidiaries’ assets and liabilities are translated into the reporting currency at period-end exchange rates, while revenue, expenses, gains and losses are translated at the average exchange rates during the period. Gains and losses from foreign currency translations are recorded in “Accumulated other comprehensive income (loss)” in the Company’s Consolidated Balance Sheets and presented as “Foreign currency translation adjustments” in the Company’s Consolidated Statements of Comprehensive Income (Loss).
Derivative Financial Instruments	Derivative Financial Instruments The Company has transactions and balances denominated in currencies other than the functional currency of the transacting entity. Most of these transactions carry foreign exchange risk in Germany, the United Kingdom and China. The Company enters into foreign exchange contracts to reduce its exposure to currency fluctuations. The arrangements typically mature in three months or less and they do not qualify for hedge accounting. Net gains and losses related to these contracts are recorded as a component of “Other income (expenses)” in the accompanying unaudited Consolidated Statements of Operations and are as follows for the three and six months ended March 31, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ March 31, ​ March 31, ​ ​ 2023 2022 2023 2022 Realized gains (losses) on derivatives not designated as hedging instruments ​ $ (533) ​ $ 1,125 ​ $ (2,112) ​ $ 1,054 ​ ​ The fair values of the forward contracts are recorded in the accompanying unaudited Consolidated Balance Sheets as “Prepaid expenses and other current assets” and “Accrued expenses and other current liabilities”. Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy described below due to a lack of an active market for these contracts.
Hedging Activities	Hedging Activities On February 1, 2022, the Company entered into a cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged approximately $1.03 billion for approximately €915 million at a weighted average interest rate of approximately 1.196% . The designated notional amount is $960 million and the actual interest rate is 1.283% . The 1.283% rate was in the range of the market value for that day and is the true interest rate on the notional amount. The Company designated the cross-currency swap as a hedge of net investments against one of our Euro denominated subsidiaries which requires an exchange of the notional amounts at maturity. At the maturity of the cross currency-swap on February 1, 2023, the Company delivered a notional amount of €852 million and received a notional amount of $960 million at an exchange rate of 1.1261 , which includes realization of a gain of $29.3 million, which was recorded in “Accumulated other comprehensive income (loss)”. On February 1, 2023, the Company entered into another cross-currency swap agreement to hedge the variability of exchange rate impacts between the U.S. dollar and the Euro. Under the terms of the cross-currency swap agreement, the Company notionally exchanged approximately . The Company designated the cross-currency swap as a hedge of net investments against one of its Euro denominated subsidiaries, which requires an exchange of the notional amounts at maturity on February 1, 2024. The cross-currency swaps are marked to market at each reporting period, representing the fair values of the cross-currency swap and any changes in fair value are recognized as a component of “Accumulated other comprehensive items, net,” on the Consolidated Statements of Comprehensive Income (Loss). Interest accrued on the cross-currency swap is recorded within “Interest income” on the Consolidated Statements of Operations. For the three and six months ended March 31, 2023, the Company recorded a net loss of $13.1 and $70.3 million, respectively to “Accumulated other comprehensive income (loss)” and recorded “Interest income” of $2.2 million and $5.3 million on these instrument for the three and six months ended March 31, 2023, respectively.
Fair Value Measurement	Fair Value Measurement The Company measures certain financial assets and liabilities, including cash equivalents, available-for-sale securities, accounts receivable, accounts payable, contingent consideration liability and derivative instruments at fair value. The Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement (“ASC 820”) establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Available-for-sale securities and derivative instruments are measured at fair value based on quoted market prices or observable inputs other than quoted market prices for identical or similar assets or liabilities. Contingent consideration liabilities that are recorded at fair value are based on level 3 inputs. The carrying amounts of cash equivalents, accounts receivable and accounts payable approximate their fair value due to their short-term nature.
Accounts Receivable and Allowance for Expected Credit Losses and Sales Returns	Accounts Receivable and Allowance for Expected Credit Losses and Sales Returns Trade accounts receivable do not bear interest and are recorded at the invoiced amount. The Company maintains an allowance for expected credit losses representing its best estimate of expected credit losses related to its existing accounts receivable and their net realizable value. The Company determines the allowance based on a number of factors, including an evaluation of customer credit worthiness, the age of the outstanding receivables, economic trends, historical experience and other information over the payment periods. The Company reviews and adjusts the allowance for expected credit losses on a quarterly basis. Accounts receivable balances are written off against the allowance for expected credit losses when the Company determines that the balances are not recoverable. Provisions for expected credit losses are recorded in “Selling, general and administrative” expenses in the Consolidated Statements of Operations. The Company determines the allowance for sales returns based on its best estimate of expected customer returns. Provisions for sales returns are recorded in “Revenue” in the Consolidated Statements of Operations. The Company does not have any off-balance-sheet credit exposure related to its customers.
Leases	Leases The Company has operating leases for real estate and non-real estate and finance leases for non-real estate. The classification of a lease as operating or finance and the determination of the right-of-use asset (“ROU asset”) and lease liability are determined at lease inception. The ROU asset represents the Company’s right to use an underlying asset for the lease term and the lease liability represents the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, an incremental borrowing rate is used based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company’s lease agreements may contain lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. Fixed payments for non-lease components are combined with lease payments and accounted for as a single lease component which increases the amount of the ROU asset and liability. The ROU asset for operating leases is included within “Other assets” and the ROU asset for finance leases is included within “Property, plant, and equipment, net” in the accompanying unaudited Consolidated Balance Sheets. The short-term lease liabilities for both operating leases and finance leases are included within “Accrued expenses and other current liabilities” in the accompanying unaudited Consolidated Balance Sheets. The long-term lease liabilities for operating leases and finance leases are included within “Long-term operating lease liabilities”, and “Other long-term liabilities”, respectively, in the accompanying unaudited Consolidated Balance Sheets.
Recently Issued and Adopted Accounting Pronouncements	Recently Issued Accounting Pronouncements In March 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting . In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope. The ASUs provide temporary optional expedients and exceptions to the GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (LIBOR) and other interbank offered rates to alternative reference rates. The provisions of the ASUs are only available until December 31, 2022, when the reference rate replacement activity was expected to be completed. There were no significant accounting impacts on the Company’s consolidated financial statements and related disclosures as a result of the adoption of these ASU’s. “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,” Recently Adopted Accounting Pronouncements In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance . The amendment in this ASU requires disclosures to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. This ASU is effective for annual periods beginning after December 15, 2021. The Company will adopt the provisions of this ASU in fiscal 2023 . ​ In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . ASU 2021-08 requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”) . Under current GAAP, an acquirer generally recognizes such items at fair value on the acquisition date. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The standard should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted the guidance during the first quarter of fiscal year 2022 . The impact of the adoption of this ASU is immaterial to the Company’s consolidated financial statements. In October 2020, the FASB issued ASU 2020-10, Codification Improvements . The amendments in this ASU represent changes to clarify certain ASCs, correct unintended application of guidance, or make minor improvements to certain ASCs that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. ASU 2020-10 is effective for annual periods beginning after December 15, 2020 and interim periods within those annual periods, with early adoption permitted. The amendments in this ASU should be applied retrospectively. This ASU did not affect the Company's consolidated financial statements or disclosures. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . In June 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) In August 2018, the FASB issued ASU 2018-14, Disclosure Framework — Changes to the Disclosure Requirements for Defined Benefit Plans , which amends ASC 715, Compensation – Retirement Benefits to add, remove, and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The amendments require additional disclosure for the weighted-average interest crediting rates, a narrative description of the reasons for significant gains and losses, and an explanation of any other significant changes in the benefit obligation or plan assets. The amendment removes disclosure requirements for accumulated other comprehensive income or loss expected to be recognized over the next year, information about plan assets to be returned to the entity, and the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost, and the benefit obligation for postretirement health care benefits. The ASU is effective for fiscal years ending after December 15, 2020. Early adoption was permitted. The ASU does not amend the interim disclosure requirements of ASC 715-20. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740) , which removes certain exceptions to the general principles in Topic 740 and improves consistent application of and simplifies GAAP for other areas of Topic 740 clarifying and amending existing guidance. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2020. Early adoption was permitted. The Company adopted the provisions of this ASU in the first quarter of fiscal 2022 . There is no significant accounting impact on the Company’s consolidated financial statements and related disclosures as a result of the adoption of this ASU.
Other	Other For further information with regard to the Company’s significant accounting policies, please refer to Note 2 “Summary of Significant Accounting Policies” to the Company’s consolidated financial statements included in the 2022 Annual Report on Form 10-K.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of realized gains (losses) on derivatives not designated as hedging instruments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ March 31, ​ March 31, ​ ​ 2023 2022 2023 2022 Realized gains (losses) on derivatives not designated as hedging instruments ​ $ (533) ​ $ 1,125 ​ $ (2,112) ​ $ 1,054 ​ ​

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Mar. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]
Schedule of discontinued operations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ ​ Six Months Ended March 31, ​ ​ ​ 2022 ​ ​ 2022 Revenue ​ ​ ​ ​ ​ ​ ​ ​ Products ​ ​ ​ $ 56,722 ​ ​ $ 244,962 Services ​ ​ ​ ​ 4,038 ​ ​ ​ 19,468 Total revenue ​ ​ ​ ​ 60,760 ​ ​ ​ 264,430 Cost of revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ Products ​ ​ ​ ​ 33,568 ​ ​ ​ 141,165 Services ​ ​ ​ ​ 2,850 ​ ​ ​ 11,159 Total cost of revenue ​ ​ ​ ​ 36,418 ​ ​ ​ 152,324 Gross profit ​ ​ ​ ​ 24,342 ​ ​ ​ 112,106 Operating expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ ​ ​ ​ 4,746 ​ ​ ​ 18,486 Selling, general and administrative ​ ​ ​ ​ 7,466 ​ ​ ​ 30,142 Total operating expenses ​ ​ ​ ​ 12,212 ​ ​ ​ 48,628 Operating income ​ ​ ​ ​ 12,130 ​ ​ ​ 63,478 Gain on divestiture ​ ​ ​ ​ 2,561,420 ​ ​ ​ 2,561,374 Income before income taxes ​ ​ ​ ​ 2,573,550 ​ ​ ​ 2,624,852 Income tax provision ​ ​ ​ ​ 451,860 ​ ​ ​ 462,700 Net income from discontinued operations ​ ​ ​ $ 2,121,690 ​ ​ $ 2,162,152 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ Six Months Ended March 31, ​ ​ ​ ​ ​ 2022 ​ ​ ​ 2022 Depreciation and amortization ​ ​ ​ $ - ​ ​ $ - Capital expenditures ​ ​ ​ $ 579 ​ ​ $ 2,862 Stock-based compensation ​ ​ ​ $ 3,109 ​ ​ $ 8,032 ​ ​ ​ ​ ​ ​

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Summary of Amortized Cost and Fair Value, Including Accrued Interest Receivable and Unrealized Holding Gains (Losses) on Short-term and Long-term Marketable Securities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross Gross ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ ​ ​ ​ Cost ​ Losses ​ Gains ​ Fair Value March 31, 2023: ​ ​ ​ ​ U.S. Treasury securities and obligations of U.S. government agencies $ 435,258 ​ $ (3,672) ​ $ 31 $ 431,617 Bank certificates of deposits ​ ​ 10,355 ​ ​ (187) ​ ​ 1 ​ ​ 10,169 Corporate securities ​ ​ 341,868 ​ ​ (5,370) ​ ​ — ​ ​ 336,498 Municipal securities ​ 1,544 ​ ​ (1) ​ ​ — ​ 1,543 ​ ​ $ 789,025 ​ $ (9,230) ​ $ 32 ​ $ 779,827 September 30, 2022: ​ ​ ​ ​ ​ U.S. Treasury securities and obligations of U.S. government agencies ​ $ 804,774 $ (6,163) $ 21 ​ $ 798,632 Bank certificates of deposits ​ ​ 8,335 ​ ​ (158) ​ ​ 1 ​ ​ 8,178 Corporate securities ​ ​ 406,270 ​ ​ (8,113) ​ ​ — ​ ​ 398,157 Municipal securities ​ 59,043 ​ ​ (226) ​ ​ — ​ 58,817 ​ ​ $ 1,278,422 ​ $ (14,660) ​ $ 22 ​ $ 1,263,784 ​
Fair Value of Marketable Securities by Contractual Maturity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortized ​ ​ ​ ​ ​ ​ Cost ​ ​ Fair Value Due in one year or less ​ ​ ​ $ 515,364 ​ $ 513,652 Due after one year through five years ​ ​ ​ 270,591 ​ 263,105 Due after five years through ten years ​ ​ ​ ​ — ​ ​ — Due after ten years ​ ​ ​ 3,070 ​ 3,070 Total marketable securities ​ ​ ​ $ 789,025 ​ $ 779,827 ​

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Mar. 31, 2023
Business Combinations [Abstract]
Amounts of Assets and Liabilities at Fair Value as of Acquisition Date	​ ​ ​ ​ ​ ​ Fair Value of ​ ​ Assets and ​ ​ Liabilities Accounts receivable ​ ​ 19,549 Inventory ​ 49,497 Other assets ​ 10,769 Property plant and equipment ​ 54,149 Identifiable Intangible Assets: ​ ​ Completed technology ​ 100,600 Trademarks ​ 5,500 Customer relationships ​ 36,700 Backlog ​ 600 Other liabilities ​ (31,080) Deferred income taxes, net ​ ​ (42,974) Goodwill ​ ​ 228,851 Total purchase price, net of cash acquired ​ $ 432,160 ​
Pro Forma Information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended, March 31, ​ ​ ​ ​ Six Months Ended, March 31, ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenue ​ $ 148,401 ​ $ ​ 178,812 ​ ​ ​ $ 326,767 ​ ​ $ 357,433 ​ Net (loss) income ​ ​ (3,233) ​ $ ​ 2,117,936 ​ ​ ​ ​ (9,078) ​ ​ ​ 2,150,720 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Components of Goodwill by Business Segment	The changes in the Company’s goodwill by reportable segment for the six months ended March 31, 2023 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences ​ Life Sciences ​ ​ ​ ​ ​ Products ​ Services ​ Total Balance, at September 30, 2022 ​ $ 154,612 ​ $ 359,011 ​ $ 513,623 Acquisitions ​ 228,851 ​ — ​ 228,851 Currency translation adjustments ​ ​ 47,998 ​ ​ 22 ​ ​ 48,020 Balance, at March 31, 2023 ​ $ 431,461 ​ $ 359,033 ​ $ 790,494 ​
Schedule of intangible assets	The components of the Company’s identifiable intangible assets as of March 31, 2023 and September 30, 2022 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2023 ​ September 30, 2022 ​ ​ ​ ​ Accumulated ​ Net Book ​ ​ ​ Accumulated ​ Net Book ​ Cost Amortization Value Cost Amortization Value Patents ​ $ 8,996 ​ $ 8,911 ​ $ 85 ​ $ 1,225 ​ $ 1,106 ​ $ 119 Completed technology ​ 258,146 ​ 85,726 ​ 172,420 ​ 99,525 ​ 37,991 ​ 61,534 Trademarks and trade names ​ 8,848 ​ 2,865 ​ 5,983 ​ 400 ​ 41 ​ 359 Non-competition agreements ​ ​ 731 ​ ​ 553 ​ ​ 178 ​ ​ 681 ​ ​ 439 ​ ​ 242 Customer relationships ​ 321,024 ​ 176,432 ​ 144,592 ​ 246,949 ​ 130,802 ​ 116,147 Other intangibles ​ ​ 896 ​ ​ 227 ​ ​ 669 ​ ​ 202 ​ ​ 202 ​ ​ — ​ ​ $ 598,641 ​ $ 274,714 ​ $ 323,927 ​ $ 348,982 ​ $ 170,581 ​ $ 178,401 ​
Schedule of Future Amortization Expense	Estimated future amortization expense for the intangible assets for the remainder of fiscal year 2023, the subsequent four fiscal years and thereafter is as follows (in thousands): ​ ​ ​ ​ 2023 ​ $ 24,217 2024 ​ 50,542 2025 ​ 49,151 2026 ​ 45,754 2027 ​ ​ 37,573 Thereafter ​ ​ 116,690 Total ​ $ 323,927

Leases (Tables)

Leases (Tables)	6 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Schedule of leases	The components of lease expense were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease costs ​ ​ ​ $ 3,086 ​ $ 2,389 ​ $ 6,150 ​ $ 4,560 ​ Finance lease costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of assets ​ ​ ​ ​ 151 ​ ​ 54 ​ ​ 242 ​ ​ 129 ​ Interest on lease liabilities ​ ​ ​ ​ 9 ​ ​ 2 ​ ​ 13 ​ ​ 5 ​ Total finance lease costs ​ ​ ​ ​ 160 ​ ​ 56 ​ ​ 255 ​ ​ 134 ​ Variable lease costs ​ ​ ​ ​ - ​ ​ 755 ​ ​ 2 ​ ​ 1,272 ​ Short-term lease costs ​ ​ ​ ​ 226 ​ ​ 364 ​ ​ 410 ​ ​ 718 ​ Sublease income ​ ​ ​ ​ (2) ​ ​ - ​ ​ (4) ​ ​ - ​ Total lease costs ​ ​ ​ $ 3,470 ​ $ 3,564 ​ $ 6,813 ​ $ 6,684 ​ ​ Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2023 ​ September 30, 2022 ​ Operating Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 63,122 ​ $ 54,059 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 8,778 ​ $ 6,924 ​ Long-term operating lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 57,137 ​ ​ 49,227 ​ Total operating lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 65,915 ​ $ 56,151 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Property, plant and equipment, at cost ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 4,010 ​ $ 2,476 ​ Accumulated amortization ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (2,504) ​ ​ (2,276) ​ Property, plant and equipment, net ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 1,506 ​ $ 200 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other current liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 543 ​ $ 96 ​ Other long-term liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1,129 ​ ​ 98 ​ Total finance lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 1,672 ​ $ 194 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining lease term (in years): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 10.10 ​ ​ 10.82 ​ Finance leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 3.46 ​ ​ 2.19 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average discount rate: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 4.04 % ​ 3.93 % Finance leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2.44 % ​ 1.29 % ​ Supplemental cash flow information related to leases was as follows (in thousands, unaudited): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ Cash paid for amounts included in measurement of liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ ​ ​ $ 2,631 ​ $ 1950 ​ $ 5,200 ​ $ 3,599 ​ Operating cash flows from finance leases ​ ​ ​ ​ 9 ​ ​ 1 ​ ​ 13 ​ ​ 4 ​ Financing cash flows from finance leases ​ ​ ​ ​ 139 ​ ​ 127 ​ ​ 226 ​ ​ 312 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ROU assets obtained in exchange for lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ ​ $ 7,230 ​ $ 7,327 ​ $ 6,464 ​ $ 7,490 ​ Finance leases ​ ​ ​ ​ 270 ​ ​ - ​ ​ 1,060 ​ ​ - ​
Schedule of future lease payments of operating leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases Operating Leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 298 ​ $ 5,779 ​ 2024 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 540 ​ ​ 10,613 ​ 2025 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 450 ​ ​ 10,316 ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 308 ​ ​ 7,974 ​ 2027 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 135 ​ ​ 7,552 ​ Thereafter ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 17 ​ ​ 39,860 ​ Total future lease payments ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1,748 ​ ​ 82,094 ​ Less imputed interest ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (76) ​ ​ (16,179) ​ Total lease liability balance ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 1,672 ​ $ 65,915 ​
Schedule of future lease payments of finance leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Finance Leases Operating Leases ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 298 ​ $ 5,779 ​ 2024 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 540 ​ ​ 10,613 ​ 2025 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 450 ​ ​ 10,316 ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 308 ​ ​ 7,974 ​ 2027 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 135 ​ ​ 7,552 ​ Thereafter ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 17 ​ ​ 39,860 ​ Total future lease payments ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1,748 ​ ​ 82,094 ​ Less imputed interest ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (76) ​ ​ (16,179) ​ Total lease liability balance ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 1,672 ​ $ 65,915 ​

Other Balance Sheet Informati_2

Other Balance Sheet Information (Tables)	6 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Accounts Receivable	The following is a summary of accounts receivable at March 31, 2023 and September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ September 30, ​ ​ 2023 2022 Accounts receivable ​ $ 175,656 ​ $ 168,920 ​ Less allowance for expected credit losses ​ (7,696) ​ (5,162) ​ Accounts receivable, net ​ $ 167,960 ​ $ 163,758 ​ ​
Allowance for Doubtful Accounts Activity	The allowance for expected credit losses for the six months ended March 31, 2023 and fiscal year ended September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at ​ ​ ​ ​ Reversals of ​ Write- ​ Balance at ​ ​ Beginning of ​ ​ ​ ​ Bad Debt ​ offs and ​ End of Description Period Provisions Expense Adjustments Period Six months ended March 31, 2023 allowance for expected credit losses ​ $ 5,162 ​ ​ 4,858 ​ ​ (2,254) ​ $ (70) ​ $ 7,696 Fiscal year 2022 allowance for expected credit losses ​ 4,318 ​ ​ 3,020 ​ ​ (2,510) ​ $ (414) ​ ​ 4,414 ​
Summary of Inventories	The following is a summary of inventories at March 31, 2023 and September 30, 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, September 30, ​ ​ 2023 2022 Inventories ​ Raw materials and purchased parts $ 71,912 $ 39,685 ​ Work-in-process ​ 5,065 ​ 4,816 ​ Finished goods ​ 73,750 ​ 41,043 ​ Total inventories $ 150,727 $ 85,544 ​ ​
Product Warranty and Retrofit Activity on Gross Basis	The following is a summary of product warranty and retrofit activity on a gross basis for the three and six months ended March 31, 2023 and 2022 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Three Months Ended March 31, 2023 Balance ​ ​ ​ ​ ​ ​ ​ Balance December 31, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ ​ Adjustments for Acquisitions ​ Accruals ​ Costs Incurred ​ 2023 $ 5,179 ​ ​ — ​ $ 1,222 ​ $ (1,021) ​ $ 5,380 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Three Months Ended March 31, 2022 Balance ​ ​ ​ ​ ​ ​ ​ Balance December 31, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2021 ​ ​ Adjustments for Acquisitions ​ Accruals ​ Costs Incurred ​ 2022 $ 2,342 ​ ​ — ​ $ 539 ​ $ (390) ​ $ 2,491 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Six Months Ended March 31, 2023 Balance ​ ​ ​ ​ ​ ​ ​ Balance September 30, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 ​ ​ Adjustments for Acquisitions ​ Accruals ​ Costs Incurred ​ 2023 $ 2,890 ​ ​ 2,303 ​ $ 1,529 ​ $ (1,342) ​ $ 5,380 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Activity -Six Months Ended March 31, 2022 Balance ​ ​ ​ ​ ​ ​ ​ Balance September 30, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2021 ​ ​ Adjustments for Acquisitions ​ Accruals ​ Costs Incurred ​ 2022 $ 2,330 ​ ​ — ​ $ 1,212 ​ $ (1,051) ​ $ 2,491

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Mar. 31, 2023
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ 2023 2022 2023 2022 Restricted stock units ​ $ 3,634 ​ $ 8,058 ​ $ 5,393 ​ $ 15,255 ​ Employee stock purchase plan ​ 356 ​ 599 ​ 703 ​ 1,293 ​ Total stock-based compensation expense ​ $ 3,990 ​ $ 8,657 ​ $ 6,096 ​ $ 16,548 ​ ​
Restricted Stock Unit Activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Time-Based Stock Performance- ​ ​ Total Units ​ Units ​ Grants ​ Based Units Six months ended March 31, 2023 572,111 356,410 — 215,701 Six months ended March 31, 2022 228,468 ​ 101,706 16,286 110,476 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ ​ Grant-Date ​ ​ Shares ​ Fair Value Outstanding at September 30, 2022 538,238 ​ $ 71.99 Granted 572,111 ​ ​ 58.21 Vested (261,618) ​ ​ 55.66 Forfeited (81,878) ​ ​ 78.66 Outstanding at March 31, 2023 766,853 ​ ​ 67.68 ​

Earnings per Share (Tables)

Earnings per Share (Tables)	6 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Reconciliation of Weighted Average Common Shares Outstanding for Purposes of Calculating Basic and Diluted Earnings Per Share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ March 31, ​ March 31, ​ ​ 2023 2022 2023 2022 Income (loss) from continuing operations ​ $ (1,991) ​ $ (1,816) ​ $ (13,226) ​ $ 1,041 ​ Income (loss) from discontinued operations, net of tax ​ (2,936) ​ 2,121,690 ​ (2,936) ​ 2,162,152 ​ Net income (loss) ​ $ (4,927) ​ $ 2,119,874 ​ $ (16,162) ​ $ 2,163,193 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding used in computing basic income (loss) per share ​ 69,111 ​ 74,958 ​ 70,858 ​ 74,823 ​ Dilutive restricted stock units ​ — ​ — ​ — ​ 322 ​ Weighted average common shares outstanding used in computing diluted income (loss) per share ​ 69,111 ​ 74,958 ​ 70,858 ​ 75,145 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic net income (loss) per share: ​ ​ ​ ​ ​ Income (loss) from continuing operations ​ $ (0.03) ​ $ (0.02) ​ $ (0.19) ​ $ 0.01 ​ Income (loss) from discontinued operations, net of tax ​ (0.04) ​ 28.31 ​ (0.04) ​ 28.90 ​ Basic net income (loss) per share ​ $ (0.07) ​ $ 28.28 ​ $ (0.23) ​ $ 28.91 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diluted net income (loss) per share: ​ ​ ​ ​ ​ Income (loss) from continuing operations ​ $ (0.03) ​ $ (0.02) ​ $ (0.19) ​ $ 0.01 ​ Income (loss) from discontinued operations, net of tax ​ (0.04) ​ 28.31 ​ (0.04) ​ 28.77 ​ Diluted net income (loss) per share ​ $ (0.07) ​ $ 28.28 ​ $ (0.23) ​ $ 28.79 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	6 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue by Reporting Unit	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ ​ Six months ended March 31, ​ ​ ​ ​ 2023 ​ ​ 2022 ​ ​ ​ 2023 ​ 2022 Significant Business Line ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products, excluding B Medical ​ ​ ​ $ 43,738 ​ ​ $ 53,615 ​ ​ $ 91,576 ​ $ 103,493 B Medical ​ ​ ​ ​ 15,122 ​ ​ ​ - ​ ​ ​ 56,944 ​ ​ - Sample Repository Solutions ​ ​ ​ ​ 27,305 ​ ​ ​ 26,929 ​ ​ ​ 54,921 ​ ​ 52,805 Genomic Services ​ ​ ​ ​ 62,236 ​ ​ ​ 65,000 ​ ​ ​ 123,326 ​ ​ 128,898 Total ​ ​ ​ $ 148,401 ​ ​ $ 145,544 ​ ​ $ 326,767 ​ $ 285,196 ​
Remaining Performance Obligations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of March 31, 2023 ​ ​ Less than 1 Year ​ Greater than 1 Year ​ Total Remaining Performance Obligations ​ $ 58,944 ​ $ 32,516 ​ $ 91,460 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	6 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Financial Information for Business Segments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ Six Months Ended March 31, ​ ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ Revenue: ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ 58,860 ​ $ 53,615 ​ $ 148,520 ​ $ 103,487 ​ Life Sciences Services ​ ​ 89,541 ​ 91,929 ​ 178,247 ​ 181,709 ​ Total revenue ​ ​ $ 148,401 ​ $ 145,544 ​ $ 326,767 ​ $ 285,196 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating income / (loss): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ $ (16,404) ​ $ 5,288 ​ $ (20,202) ​ $ 9,679 ​ Life Sciences Services ​ ​ (4,878) ​ 4,856 ​ (9,490) ​ 12,740 ​ Reportable segment operating income (loss) ​ ​ ​ (21,282) ​ ​ 10,144 ​ ​ (29,692) ​ ​ 22,419 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization of completed technology ​ ​ ​ 4,901 ​ ​ 1,840 ​ ​ 9,070 ​ ​ 3,613 ​ Purchase accounting impact on inventory ​ ​ ​ 2,912 ​ ​ — ​ ​ 5,781 ​ ​ — ​ Amortization of other intangible assets ​ ​ ​ 7,509 ​ ​ 6,047 ​ ​ 14,882 ​ ​ 12,319 ​ Restructuring charges ​ ​ ​ 1,499 ​ ​ 122 ​ ​ 2,961 ​ ​ 295 ​ Contingent consideration - fair value adjustments ​ ​ ​ (17,145) ​ ​ — ​ ​ (17,145) ​ ​ — ​ Tariff adjustment ​ ​ ​ — ​ ​ (486) ​ ​ — ​ ​ (486) ​ Other unallocated corporate expenses ​ ​ ​ (7,981) ​ ​ 7,329 ​ ​ (4,579) ​ ​ 11,711 ​ Total operating income (loss) ​ ​ ​ (12,977) ​ ​ (4,708) ​ ​ (40,662) ​ ​ (5,033) ​ Interest income ​ ​ ​ 10,394 ​ ​ 3,076 ​ ​ 21,059 ​ ​ 3,111 ​ Interest expense ​ ​ ​ — ​ ​ (1,555) ​ ​ — ​ ​ (2,010) ​ Loss on extinguishment of debt ​ ​ ​ — ​ ​ (632) ​ ​ — ​ ​ (632) ​ Other income (expense) ​ ​ ​ (2,668) ​ ​ (1,170) ​ ​ (1,523) ​ ​ (2,248) ​ (Loss) before income taxes ​ ​ $ (5,251) ​ $ (4,989) ​ $ (21,126) ​ $ (6,812) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ Life Sciences Products ​ ​ Life Sciences Services ​ ​ Total ​ March 31, 2023 ​ ​ ​ ​ ​ $ 948,580 ​ $ 849,018 ​ $ 1,797,598 ​ September 30, 2022 ​ ​ ​ ​ ​ 378,790 ​ ​ 849,603 ​ 1,228,393 ​ ​
Reconciliation of Reportable Segment Assets to Corresponding Consolidated Amounts	​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, September 30, ​ ​ 2023 ​ 2022 Segment assets $ 1,797,598 $ 1,228,393 Cash and cash equivalents, restricted cash, and marketable securities ​ 1,451,703 ​ 2,305,081 Deferred tax assets ​ 490 ​ 1,169 Other assets ​ ​ 23 ​ ​ 181,479 Total assets ​ $ 3,249,814 ​ $ 3,716,122 ​
Revenue from External Customers Attributed to Geographic Areas	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ Six Months Ended March 31, ​ ​ ​ 2023 ​ 2022 ​ 2023 ​ 2022 ​ ​ Geographic Location: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ North America ​ $ 87,484 ​ $ 94,283 ​ $ 176,419 ​ $ 184,366 ​ ​ Rest of Europe ​ ​ 21,432 ​ ​ 19,745 ​ ​ 60,854 ​ ​ 40,028 ​ ​ Africa ​ ​ 8,627 ​ ​ 672 ​ ​ 25,837 ​ ​ 1,219 ​ ​ China ​ ​ 11,979 ​ ​ 13,757 ​ ​ 25,387 ​ ​ 26,798 ​ ​ Asia Pacific/ Other ​ ​ 13,090 ​ ​ 10,278 ​ ​ 27,068 ​ ​ 17,664 ​ ​ United Kingdom ​ ​ 5,789 ​ ​ 6,809 ​ ​ 11,202 ​ ​ 15,121 ​ ​ Total ​ $ 148,401 ​ $ 145,544 ​ $ 326,767 ​ $ 285,196 ​ ​ ​

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at Reporting Date Using ​ ​ ​ Quoted Prices in ​ ​ Significant ​ ​ ​ ​ ​ Active Markets for ​ Significant Other ​ Unobservable ​ ​ March 31, ​ Identical Assets ​ Observable Inputs ​ Inputs Description ​ 2023 ​ (Level 1) ​ (Level 2) ​ (Level 3) Assets: ​ ​ ​ ​ Cash equivalents ​ $ 510,643 ​ $ 499,283 ​ $ 11,360 ​ $ — Available-for-sale securities ​ 779,827 ​ 208,527 ​ ​ 571,300 ​ — Foreign exchange contracts ​ 150 ​ — ​ 150 ​ — Net investment hedge ​ 1,278 ​ — ​ 1,278 ​ — Total assets ​ $ 1,291,898 ​ $ 707,810 ​ $ 584,088 ​ $ — Liabilities: ​ ​ ​ ​ Contingent consideration liability ​ $ 1,406 ​ $ — ​ $ — ​ $ 1,406 Foreign exchange contracts ​ ​ 164 ​ ​ — ​ ​ 164 ​ ​ — Total liabilities ​ $ 1,570 ​ $ — ​ $ 164 ​ $ 1,406 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at Reporting Date Using ​ ​ ​ Quoted Prices in ​ ​ Significant ​ ​ ​ ​ ​ Active Markets for ​ Significant Other ​ Unobservable ​ ​ September 30, ​ Identical Assets ​ Observable Inputs ​ Inputs Description ​ 2022 ​ (Level 1) ​ (Level 2) ​ (Level 3) Assets: ​ ​ ​ ​ Cash equivalents ​ $ 374,804 ​ $ 374,055 ​ $ 749 ​ $ — Available-for-sale securities ​ 1,263,782 ​ 651,800 ​ 611,982 ​ — Foreign exchange contracts ​ 634 ​ — ​ 634 ​ — Net investment hedge ​ ​ 124,789 ​ ​ — ​ ​ 124,789 ​ ​ — Total assets ​ $ 1,764,009 ​ $ 1,025,855 ​ $ 738,154 ​ $ — Liabilities: ​ ​ ​ ​ Foreign exchange contracts ​ $ 230 ​ $ — ​ $ 230 ​ $ — Total liabilities ​ $ 230 ​ $ — ​ $ 230 ​ $ — ​

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Foreign Currency Translation (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Foreign Currency Transaction Gain (Loss), before Tax [Abstract]
Foreign currency transaction and remeasurement gains (losses)	$ (0.9)	$ (1.2)	$ (0.8)	$ (3.2)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Derivative Financial Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net [Abstract]
Realized gains (losses) on derivatives not designated as hedging instruments	$ (533)	$ 1,125	$ (2,112)	$ 1,054

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Hedging Activities (Details) $ in Thousands, € in Millions		3 Months Ended		6 Months Ended
	Feb. 01, 2023 USD ($) $ / €	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Feb. 01, 2023 EUR (€) $ / €	Feb. 01, 2022 USD ($)	Feb. 01, 2022 EUR (€)
Derivative [Line Items]
Net investment hedge currency translation adjustment, net of tax effect		$ (13,133)	$ 7,149	$ (70,260)	$ 7,149
Interest income		10,394	$ 3,076	21,059	$ 3,111
Currency Swap | Designated as Hedging Instrument
Derivative [Line Items]
Derivative, notional amount, cross-currency swap, exchanged	$ 436,000						$ 1,030,000
Derivative, notional amount, cross-currency swap, received | €						€ 400		€ 915
Derivative, notional amount							$ 960,000
Derivative, fixed interest rate (as a percent)							1.283%	1.283%
Derivative, notional amount, cross-currency swap, maturity, deliver | €						€ 852
Derivative, notional amount, cross-currency swap, maturity, receive	$ 960,000
Derivative, forward exchange rate | $ / €	1.1261					1.1261
Gain on derivative	$ 29,300
Gain (loss) to accumulated other comprehensive income		(13,100)		(70,300)
Interest income		$ 2,200		$ 5,300
Currency Swap | Designated as Hedging Instrument | Weighted Average
Derivative [Line Items]
Derivative, variable interest rate	1.66%					1.66%	1.196%	1.196%

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Recently Issued and Adopted Accounting Pronouncements (Details)	Mar. 31, 2023
Accounting Standards Update 2021-10
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false
Accounting Standards Update 2021-08
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Oct. 01, 2021
Accounting Standards Update 2020-10
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Oct. 01, 2021
Accounting Standards Update 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Oct. 01, 2022
Accounting Standards Update 2018-14
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Oct. 01, 2021
Accounting Standards Update 2019-12
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Oct. 01, 2021

Discontinued Operations - Gener

Discontinued Operations - General Information (Details) $ in Thousands		3 Months Ended	6 Months Ended	12 Months Ended
	Feb. 01, 2022 USD ($) lease	Mar. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Mar. 31, 2023 lease
Thomas H. Lee Partners, L.P.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Transition service agreement, term, low end of range	3 months
Transition service agreement, term, high end of range	24 months
Sale leaseback transaction, lease agreements, number | lease	2				1
Sale leaseback transaction, lease term	24 months
Sale leaseback transaction, termination notice period	90 days
Discontinued Operations, Disposed of by Sale | Semiconductor Automation Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture	$ 2,900,000
Gain on divestiture		$ 2,561,420	$ 2,561,374
Liability related to retention and stock compensation for former employees of the Company that were conveyed with the transaction	$ 18,100
Liability related to retention and stock compensation for former employees of the Company that were conveyed with the transaction, amount paid				$ 600

Discontinued Operations - Finan

Discontinued Operations - Financial Results (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Net income from discontinued operations	$ (2,936)	$ 2,121,690	$ (2,936)	$ 2,162,152
Discontinued Operations, Disposed of by Sale | Semiconductor Automation Business
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Total revenue		60,760		264,430
Total cost of revenue		36,418		152,324
Gross profit		24,342		112,106
Research and development		4,746		18,486
Selling, general and administrative		7,466		30,142
Total operating expenses		12,212		48,628
Operating income		12,130		63,478
Gain on divestiture		2,561,420		2,561,374
Income before income taxes		2,573,550		2,624,852
Income tax provision		451,860		462,700
Net income from discontinued operations	(400)	2,121,690		2,162,152
Discontinued Operations, Disposed of by Sale | Semiconductor Automation Business | Products
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Total revenue		56,722		244,962
Total cost of revenue		33,568		141,165
Discontinued Operations, Disposed of by Sale | Semiconductor Automation Business | Services
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Total revenue		4,038		19,468
Total cost of revenue		$ 2,850		$ 11,159
Discontinued Operations, Disposed of by Sale | Semiconductor Cryogenics Business
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Net income from discontinued operations	$ (2,500)

Discontinued Operations - Non-c

Discontinued Operations - Non-cash Items and Capital Expenditures (Details) - Discontinued Operations, Disposed of by Sale - Semiconductor Automation Business - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2022	Mar. 31, 2022
Discontinued Operation, Alternative Cash Flow Information [Abstract]
Capital expenditures	$ 579	$ 2,862
Stock-based compensation	$ 3,109	$ 8,032

Marketable Securities - General

Marketable Securities - General Information (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2023	Mar. 31, 2023	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Sales and maturities of marketable securities	$ 121,000	$ 728,171	$ 3,710

Marketable Securities - Summary

Marketable Securities - Summary of Amortized Cost and Fair Value (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 789,025	$ 1,278,422
Gross Unrealized Losses	(9,230)	(14,660)
Gross Unrealized Gains	32	22
Fair Value	779,827	1,263,784
U.S. Treasury securities and obligations of U.S. government agencies
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	435,258	804,774
Gross Unrealized Losses	(3,672)	(6,163)
Gross Unrealized Gains	31	21
Fair Value	431,617	798,632
Bank certificates of deposits
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	10,355	8,335
Gross Unrealized Losses	(187)	(158)
Gross Unrealized Gains	1	1
Fair Value	10,169	8,178
Corporate securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	341,868	406,270
Gross Unrealized Losses	(5,370)	(8,113)
Fair Value	336,498	398,157
Municipal securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	1,544	59,043
Gross Unrealized Losses	(1)	(226)
Fair Value	$ 1,543	$ 58,817

Marketable Securities - Fair Va

Marketable Securities - Fair Value of Marketable Securities by Contractual Maturity (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]
Amortized cost, due in one year or less, remainder of fiscal year	$ 515,364
Amortized cost, due in one year or less	0
Amortized cost, due after one year through five years	270,591
Amortized cost, due after ten years	3,070
Amortized cost	789,025
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]
Fair value, due in one year or less, remainder of fiscal year	513,652
Fair value, due in one year or less	0
Fair value, due after one year through five years	263,105
Fair value, due after ten years	3,070
Fair value	$ 779,827

Acquisitions - General Informat

Acquisitions - General Information (Details) - country	Feb. 03, 2023	Oct. 03, 2022	Jul. 01, 2022
Ziath Ltd and Subsidiaries
Business Acquisition, Date of Acquisition [Abstract]
Business Acquisition, Effective Date of Acquisition	Feb. 02, 2023
B Medical Systems S.a.r.l and Subsidiaries
Business Acquisition, Date of Acquisition [Abstract]
Business Acquisition, Effective Date of Acquisition		Oct. 03, 2022
B Medical Systems S.a.r.l and Subsidiaries | Minimum
Business Acquisition, Date of Acquisition [Abstract]
Number of countries in which entity operates		150
Barkey Holding GmbH and Subsidiaries
Business Acquisition, Date of Acquisition [Abstract]
Business Acquisition, Effective Date of Acquisition			Jul. 01, 2022

Acquisitions - Purchase Conside

Acquisitions - Purchase Consideration (Details) $ in Thousands, € in Millions				6 Months Ended
	Feb. 03, 2023 USD ($)	Oct. 03, 2022 USD ($)	Jul. 01, 2022 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Oct. 03, 2022 EUR (€)	Sep. 30, 2022 USD ($)
Business Acquisition [Line Items]
Aggregate purchase price, net of cash acquired				$ 387,665
Short-term restricted cash				4,021			$ 382,596
Contingent consideration liability				1,400	$ 18,500
Ziath Ltd and Subsidiaries
Business Acquisition [Line Items]
Aggregate purchase price, net of cash acquired	$ 16,000
B Medical Systems S.a.r.l and Subsidiaries
Business Acquisition [Line Items]
Total purchase price		$ 432,200
Contingent consideration		17,000
Aggregate purchase price, net of cash acquired		$ 424,000
Additional contingent consideration | €						€ 50
Prepaid assets							43,100
Short-term restricted cash							$ 381,000
Contingent consideration liability, achievement of certain revenue targets, term		1 year
Contingent consideration liability				$ 1,400	$ 18,500
Barkey Holding GmbH and Subsidiaries
Business Acquisition [Line Items]
Total purchase price			$ 84,800

Acquisitions - Amounts of Asset

Acquisitions - Amounts of Assets and Liabilities at Fair Value as of Acquisition Date (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Feb. 03, 2023	Oct. 03, 2022	Sep. 30, 2022	Jul. 01, 2022
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	$ 790,494			$ 513,623
Ziath Ltd and Subsidiaries
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Deferred income taxes, net		$ (1,100)
Goodwill		12,000
Ziath Ltd and Subsidiaries | Completed Technology
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets		4,100
Ziath Ltd and Subsidiaries | Trademarks
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets		300
Ziath Ltd and Subsidiaries | Customer Relationships
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets		$ 600
B Medical Systems S.a.r.l and Subsidiaries
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Accounts receivable			$ 19,549
Inventory			49,497
Other assets			10,769
Property, plant and equipment			54,149
Other liabilities			(31,080)
Deferred income taxes, net			(42,974)
Goodwill			228,851
Total purchase price, net of cash acquired			432,160
B Medical Systems S.a.r.l and Subsidiaries | Revision of Prior Period, Adjustment
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Inventory	(200)
Other assets	(9,600)
Property, plant and equipment	(1,000)
Intangible assets	400
Deferred revenue	600
Goodwill	$ 9,800
B Medical Systems S.a.r.l and Subsidiaries | Completed Technology
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets			100,600
B Medical Systems S.a.r.l and Subsidiaries | Trademarks
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets			5,500
B Medical Systems S.a.r.l and Subsidiaries | Customer Relationships
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets			36,700
B Medical Systems S.a.r.l and Subsidiaries | Order or Production Backlog
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets			$ 600
Barkey Holding GmbH and Subsidiaries
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Deferred income taxes, net					$ (9,800)
Goodwill					57,800
Barkey Holding GmbH and Subsidiaries | Completed Technology
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets					29,000
Barkey Holding GmbH and Subsidiaries | Customer Relationships
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Intangible assets					$ 3,000

Acquisitions - Intangible Asset

Acquisitions - Intangible Assets Acquired (Details)	Feb. 03, 2023	Oct. 03, 2022	Jul. 01, 2022
Ziath Ltd and Subsidiaries | Completed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets	10 years
Ziath Ltd and Subsidiaries | Customer Relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets	13 years
Ziath Ltd and Subsidiaries | Trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets	13 years
B Medical Systems S.a.r.l and Subsidiaries
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, valuation technique, discounted cash flow, measurement input, discount rate, percentage (as a percent)		13%
B Medical Systems S.a.r.l and Subsidiaries | Completed Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets		10 years
B Medical Systems S.a.r.l and Subsidiaries | Customer Relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets		16 years
B Medical Systems S.a.r.l and Subsidiaries | Trademarks
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets		5 years
B Medical Systems S.a.r.l and Subsidiaries | Order or Production Backlog
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets		1 year
Barkey Holding GmbH and Subsidiaries
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average useful life of intangible assets			15 years

Acquisitions - Goodwill (Detail

Acquisitions - Goodwill (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Feb. 03, 2023	Oct. 03, 2022	Sep. 30, 2022	Jul. 01, 2022
Business Combination, Goodwill [Abstract]
Goodwill	$ 790,494			$ 513,623
Life Sciences Products
Business Combination, Goodwill [Abstract]
Goodwill	$ 431,461			$ 154,612
Ziath Ltd and Subsidiaries
Business Combination, Goodwill [Abstract]
Goodwill		$ 12,000
Goodwill deductible for tax purposes		$ 0
B Medical Systems S.a.r.l and Subsidiaries
Business Combination, Goodwill [Abstract]
Goodwill			$ 228,851
Goodwill deductible for tax purposes			0
B Medical Systems S.a.r.l and Subsidiaries | Life Sciences Products
Business Combination, Goodwill [Abstract]
Goodwill			$ 228,800
Barkey Holding GmbH and Subsidiaries
Business Combination, Goodwill [Abstract]
Goodwill					$ 57,800
Goodwill deductible for tax purposes					$ 0

Acquisitions - Results of Opera

Acquisitions - Results of Operations (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2023	Mar. 31, 2022
Business Acquisition, Pro Forma Information [Abstract]
Amortization of intangible assets	$ 12.4	$ 7.9	$ 15.9		$ 24
B Medical Systems S.a.r.l and Subsidiaries
Business Acquisition, Pro Forma Information [Abstract]
Actual revenues	15.1		57.3
Actual net income (loss)	(10.4)		$ (13)
Acquisition related costs	$ 0.2			$ 8.9

Acquisitions - Pro Forma Inform

Acquisitions - Pro Forma Information - Tabular Disclosure (Details) - B Medical Systems S.a.r.l and Subsidiaries - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Business Acquisition, Pro Forma Information [Abstract]
Revenue	$ 148,401	$ 178,812	$ 326,767	$ 357,433
Net loss	$ (3,233)	$ 2,117,936	$ (9,078)	$ 2,150,720

Acquisitions - Pro Forma Info_2

Acquisitions - Pro Forma Information - Additional Information (Details) - B Medical Systems S.a.r.l and Subsidiaries - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Business Acquisition, Pro Forma Information [Abstract]
Business acquisition, pro forma information, purchase accounting adjustment, reversal of research and development expense capitalization		$ 1.4		$ 1.6
Business acquisition, pro forma information, purchase accounting adjustment, property, plant and equipment, inventory, and intangible asset step-up depreciation and amortization expense	$ 2.7	6.4	$ 5.4	12.7
Business acquisition, pro forma information, purchase accounting adjustment, transaction costs	$ 0.3	8.7	$ 4.9	8.9
Business acquisition, pro forma information, purchase accounting adjustment, reversal of debt interest expense		$ 5.4		$ 5.7

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill Impairment Test (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Goodwill [Line Items]
Goodwill impairment	$ 0
Life Sciences Services
Goodwill [Line Items]
Goodwill impairment test, reporting unit, estimated fair value exceeded carrying value, percentage (as a percent)	24%
Life Sciences Products
Goodwill [Line Items]
Goodwill impairment test, reporting unit, estimated fair value exceeded carrying value, percentage (as a percent)	17%

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Goodwill Roll Forward - Tabular Disclosure (Details) $ in Thousands	6 Months Ended
	Mar. 31, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 513,623
Acquisitions	228,851
Currency translation adjustments	48,020
Goodwill, ending balance	790,494
Life Sciences Products
Goodwill [Roll Forward]
Goodwill, beginning balance	154,612
Acquisitions	228,851
Currency translation adjustments	47,998
Goodwill, ending balance	431,461
Life Sciences Services
Goodwill [Roll Forward]
Goodwill, beginning balance	359,011
Currency translation adjustments	22
Goodwill, ending balance	$ 359,033

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Goodwill Roll Forward - Additional Information (Details) $ in Thousands	6 Months Ended
	Mar. 31, 2023 USD ($)
Business Combination Segment Allocation [Line Items]
Acquisitions	$ 228,851
Currency translation adjustments	48,020
B Medical Systems S.a.r.l and Subsidiaries
Business Combination Segment Allocation [Line Items]
Acquisitions	228,900
Currency translation adjustments	$ 48,000

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Components of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Finite-Lived Intangible Assets [Line Items]
Cost	$ 598,641	$ 348,982
Accumulated Amortization	274,714	170,581
Net Book Value	323,927	178,401
Patents
Finite-Lived Intangible Assets [Line Items]
Cost	8,996	1,225
Accumulated Amortization	8,911	1,106
Net Book Value	85	119
Completed Technology
Finite-Lived Intangible Assets [Line Items]
Cost	258,146	99,525
Accumulated Amortization	85,726	37,991
Net Book Value	172,420	61,534
Trademarks and Trade Names
Finite-Lived Intangible Assets [Line Items]
Cost	8,848	400
Accumulated Amortization	2,865	41
Net Book Value	5,983	359
Noncompete Agreements
Finite-Lived Intangible Assets [Line Items]
Cost	731	681
Accumulated Amortization	553	439
Net Book Value	178	242
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Cost	321,024	246,949
Accumulated Amortization	176,432	130,802
Net Book Value	144,592	116,147
Other Intangible Assets
Finite-Lived Intangible Assets [Line Items]
Cost	896	202
Accumulated Amortization	227	$ 202
Net Book Value	$ 669

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets - Intangible Assets Acquired (Details) $ in Millions	6 Months Ended
	Mar. 31, 2023 USD ($)
B Medical Systems S.a.r.l and Subsidiaries
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 150.3

Goodwill and Intangible Asset_7

Goodwill and Intangible Assets - Amortization Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 12.4	$ 7.9	$ 15.9	$ 24

Goodwill and Intangible Asset_8

Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2023	$ 24,217
2024	50,542
2025	49,151
2026	45,754
2027	37,573
Thereafter	116,690
Net Book Value	$ 323,927	$ 178,401

Leases - Lease Expense (Details

Leases - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Lease, Cost [Abstract]
Operating lease costs	$ 3,086	$ 2,389	$ 6,150	$ 4,560
Amortization of assets	151	54	242	129
Interest on lease liabilities	9	2	13	5
Total finance lease costs	160	56	255	134
Variable lease cost		755	2	1,272
Short-term lease costs	226	364	410	718
Sublease income	(2)		(4)
Total lease costs	$ 3,470	$ 3,564	$ 6,813	$ 6,684

Leases - Assets and Liabilities

Leases - Assets and Liabilities - Operating Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Assets and Liabilities, Lessee [Abstract]
Operating lease right-of-use assets	$ 63,122	$ 54,059
Operating Lease, Right-of-Use Asset, Statement of Financial Position	Other assets	Other assets
Accrued expenses and other current liabilities	$ 8,778	$ 6,924
Operating Lease, Liability, Current, Statement of Financial Position	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Long-term operating lease liabilities	$ 57,137	$ 49,227
Total lease liability balance	$ 65,915	$ 56,151

Leases - Assets and Liabiliti_2

Leases - Assets and Liabilities - Finance Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Finance Lease, Right-of-Use Asset, after Accumulated Amortization [Abstract]
Property, plant and equipment, at cost	$ 4,010	$ 2,476
Accumulated amortization	(2,504)	(2,276)
Property, plant and equipment, net	$ 1,506	$ 200
Finance Lease, Right-of-Use Asset, Statement of Financial Position	Property, plant and equipment, net	Property, plant and equipment, net
Finance Lease Liability [Abstract]
Accrued expenses and other current liabilities	$ 543	$ 96
Finance Lease, Liability, Current, Statement of Financial Position	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Other long-term liabilities	$ 1,129	$ 98
Finance Lease, Liability, Noncurrent, Statement of Financial Position	Other long-term liabilities	Other long-term liabilities
Total finance lease liabilities	$ 1,672	$ 194
Finance Lease, Liability, Statement of Financial Position	Other long-term liabilities, Accrued expenses and other current liabilities	Other long-term liabilities, Accrued expenses and other current liabilities

Leases - Additional Information

Leases - Additional Information (Details)	Mar. 31, 2023	Sep. 30, 2022
Leases [Abstract]
Weighted average remaining lease term, operating leases	10 years 1 month 6 days	10 years 9 months 25 days
Weighted average remaining lease term, finance leases	3 years 5 months 15 days	2 years 2 months 8 days
Weighted average discount rate, operating leases (as a percent)	4.04%	3.93%
Weighted average discount rate, finance leases (as a percent)	2.44%	1.29%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Cash Flow, Operating Activities, Lessee [Abstract]
Operating cash flows from operating leases	$ 2,631	$ 1,950	$ 5,200	$ 3,599
Operating cash flows from finance leases	9	1	13	4
Financing cash flows from finance leases	$ 139	$ 127	$ 226	$ 312

Leases - Assets Obtained in Exc

Leases - Assets Obtained in Exchange for Lease Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Lessee Disclosure [Abstract]
ROU assets obtained in exchange for lease liabilities, operating leases, net	$ 7,230	$ 7,327	$ 6,464	$ 7,490
ROU assets obtained in exchange for lease liabilities, finance leases	$ 270		$ 1,060

Leases - Finance Leases - Futur

Leases - Finance Leases - Future Lease Payments (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Finance Lease, Liability, to be Paid [Abstract]
2023	$ 298
2024	540
2025	450
2026	308
2027	135
Thereafter	17
Total future lease payments	$ 1,748

Leases - Finance Leases - Gross

Leases - Finance Leases - Gross Difference (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Finance Lease, Liability, to be Paid, Gross Difference [Abstract]
Total future lease payments	$ 1,748
Less imputed interest	(76)
Total finance lease liabilities	$ 1,672	$ 194

Leases - Operating Leases - Fut

Leases - Operating Leases - Future Lease Payments (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2023	$ 5,779
2024	10,613
2025	10,316
2026	7,974
2027	7,552
Thereafter	39,860
Total future lease payments	$ 82,094

Leases - Operating Leases - Gro

Leases - Operating Leases - Gross Difference (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Operating Lease Liabilities, Gross Difference, Amount [Abstract]
Total future lease payments	$ 82,094
Less imputed interest	(16,179)
Total lease liability balance	$ 65,915	$ 56,151

Income Taxes - Provision (Benef

Income Taxes - Provision (Benefit) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income tax expense (benefit)	$ (3,260)	$ (3,173)	$ (7,900)	$ (7,853)
Deferred tax benefit resulting from the extension of a tax incentive in China			1,400
Benefit related to stock compensation windfalls				4,500
Charge to increase the deferred tax liability to reflect a change in the blended state income tax rate that results from the sale of the semiconductor business assets				600
Pre-tax income not subject to income taxes	$ 17,100		$ 17,100
Pre-tax gains (losses)		$ (1,800)		$ (5,000)

Income Taxes - Examination (Det

Income Taxes - Examination (Details)	6 Months Ended
	Mar. 31, 2023
Earliest Tax Year
Income Tax Contingency [Line Items]
Year subject to examination	2017

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) $ in Millions	Mar. 31, 2023 USD ($)
Income Tax Disclosure [Abstract]
Anticipated unrecognized tax benefit reduction during next twelve months	$ 1.4

Other Balance Sheet Informati_3

Other Balance Sheet Information - Summary of Account Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Accounts receivable	$ 175,656	$ 168,920
Less allowance for expected credit losses	(7,696)	(5,162)
Accounts receivable, net	$ 167,960	$ 163,758

Other Balance Sheet Informati_4

Other Balance Sheet Information - Allowance for Expected Credit Losses Activity (Details) - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at beginning of period	$ 5,162	$ 4,318
Provisions	4,858	3,020
Reversals of bad debt expense	(2,254)	(2,510)
Write-offs and adjustments	(70)	(414)
Balance at end of period	$ 7,696	$ 4,414

Other Balance Sheet Informati_5

Other Balance Sheet Information - Summary of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials and purchased parts	$ 71,912	$ 39,685
Work-in-process	5,065	4,816
Finished goods	73,750	41,043
Inventory, net	$ 150,727	$ 85,544

Other Balance Sheet Informati_6

Other Balance Sheet Information - Inventory Reserves (Details) - USD ($) $ in Millions	Mar. 31, 2023	Sep. 30, 2022
Inventory Adjustments [Abstract]
Reserves related to write downs or adjustments of inventory to net realizable	$ 4.1	$ 4.1

Other Balance Sheet Informati_7

Other Balance Sheet Information - Capitalized Direct Costs (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Sep. 30, 2022
Property, Plant and Equipment, Gross [Abstract]
Capitalized computer software, gross	$ 28.7		$ 28.7		$ 26.9
Capitalized computer software costs	0.7	$ 0.8	1.8	$ 1.3
Software Development
Property, Plant and Equipment, Gross [Abstract]
Capitalized computer software, gross	$ 10.2		$ 10.2

Other Balance Sheet Informati_8

Other Balance Sheet Information - Product Warranty and Retrofit Activity on Gross Basis (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Beginning Balance	$ 5,179	$ 2,342	$ 2,890	$ 2,330
Adjustments for acquisitions			2,303
Accruals	1,222	539	1,529	1,212
Costs incurred	(1,021)	(390)	(1,342)	(1,051)
Ending Balance	$ 5,380	$ 2,491	$ 5,380	$ 2,491

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 3,990	$ 8,657	$ 6,096	$ 16,548
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	3,634	8,058	5,393	15,255
Restricted Stock Units (RSUs) | Continuing Operations
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	3,900	5,200	5,800	7,700
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	356	599	703	1,293
Employee Stock | Continuing Operations
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 400	$ 400	$ 700	$ 800

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units Granted (Details) - shares	6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	572,111	228,468
Restricted Stock, Time Based Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	356,410	101,706
Board of Director Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)		16,286
Restricted Stock, Performance Based Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stocks granted (in shares)	215,701	110,476

Stock-Based Compensation - Time

Stock-Based Compensation - Time-Based Restricted Stock Unit Grants (Details) - Restricted Stock, Time Based Shares	6 Months Ended
	Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)	3 years
Share-Based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage (as a percent)	33.33%
Share-Based Payment Arrangement, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage (as a percent)	33.33%
Share-Based Payment Arrangement, Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting percentage (as a percent)	33.33%

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance-Based Restricted Stock Unit Grants (Details)	6 Months Ended	12 Months Ended
	Mar. 31, 2023	Sep. 30, 2022	Sep. 30, 2021
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Performance-based awards granted, percentage (as a percent)	100%	100%	100%
Performance-based awards granted, percentage, maximum threshold met (as a percent)	200%	200%	200%
Performance goal measurement period (in years)	3 years

Stock-Based Compensation - Re_2

Stock-Based Compensation - Restricted Stock Unit Activity - Tabular Disclosure (Details) - Restricted Stock Units (RSUs) - $ / shares	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Shares
Outstanding at beginning of period (in shares)			538,238
Restricted stocks granted (in shares)			572,111	228,468
Vested (in shares)			(261,618)
Forfeited (in shares)			(81,878)
Outstanding at end of period (in shares)	766,853		766,853
Weighted Average Grant-Date Fair Value
Outstanding at beginning of period (in dollars per share)			$ 71.99
Granted (in dollars per share)	$ 58.21	$ 82.34	58.21
Vested (in dollars per share)			55.66
Forfeited (in dollars per share)			78.66
Outstanding at end of period (in dollars per share)	$ 67.68		$ 67.68

Stock-Based Compensation - Re_3

Stock-Based Compensation - Restricted Stock Unit Activity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Withholding tax payments on net share settlements on equity awards			$ 4,906
Proceeds from employees to satisfy tax obligation	$ 0
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in dollars per share)	$ 58.21	$ 82.34	$ 58.21
Fair value of restricted stock awards vested	$ 2,600	$ 1,900
Withholding taxes remitted			$ 4,900	$ 25,100
Withholding tax payments on net share settlements on equity awards			$ 4,900	0
Proceeds from employees to satisfy tax obligation				$ 0

Stock-Based Compensation - Re_4

Stock-Based Compensation - Restricted Stock Unit Activity - Unrecognized Compensation Cost (Details) - Restricted Stock Units (RSUs) $ in Millions	6 Months Ended
	Mar. 31, 2023 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 31.1
Unrecognized compensation cost, estimated weighted average amortization period	2 years 14 days

Stock-Based Compensation - Empl

Stock-Based Compensation - Employee Stock Purchase Plan (Details) - shares	6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued under employee stock purchase plan (in shares)	39,479	51,133
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock (as a percent)	85%

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) shares in Millions			1 Months Ended	6 Months Ended
	Apr. 05, 2023	Nov. 28, 2022	Apr. 30, 2023	Mar. 31, 2023	Nov. 04, 2022	Sep. 29, 2015
Equity, Class of Treasury Stock [Line Items]
Payments for repurchase of common stock				$ 500,000,000
Share Repurchase Program, September 2015
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount					$ 0	$ 50,000,000
Share Repurchase Program, November 2022
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount					1,500,000,000
Stock repurchase program, remaining authorized repurchase amount				$ 1,000,000,000
Share Repurchase Program, November 2022, Accelerated Share Repurchase Agreement
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount					$ 500,000,000
Payments for repurchase of common stock		$ 500,000,000
Stock repurchased and retired during period (in shares)		6.1
Stock repurchase program, percentage of common stock expected to be repurchased under program (as a percent)		70%
Share Repurchase Program, November 2022, Accelerated Share Repurchase Agreement | Subsequent Event
Equity, Class of Treasury Stock [Line Items]
Stock repurchased and retired during period (in shares)	4
Share Repurchase Program, April 2023 | Subsequent Event
Equity, Class of Treasury Stock [Line Items]
Stock repurchase program, authorized amount			$ 500,000,000
Stock repurchased and retired during period (in shares)			10

Earnings per Share - Tabular Di

Earnings per Share - Tabular Disclosure (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Income (loss) from continuing operations	$ (1,991)	$ (1,816)	$ (13,226)	$ 1,041
Income (loss) from discontinued operations, net of tax	(2,936)	2,121,690	(2,936)	2,162,152
Net income (loss)	(4,927)	2,119,874	(16,162)	2,163,193
Net income - basic	(4,927)	2,119,874	(16,162)	2,163,193
Net income - diluted	$ (4,927)	$ 2,119,874	$ (16,162)	$ 2,163,193
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Weighted average common shares outstanding used in computing basic income (loss) per share (in shares)	69,111	74,958	70,858	74,823
Dilutive restricted stock units (in shares)				322
Weighted average common shares outstanding used in computing diluted income (loss) per share (in shares)	69,111	74,958	70,858	75,145
Earnings Per Share, Basic [Abstract]
Income (loss) from continuing operations (in dollars per share)	$ (0.03)	$ (0.02)	$ (0.19)	$ 0.01
Income (loss) from discontinued operations, net of tax (in dollars per share)	(0.04)	28.31	(0.04)	28.90
Basic net income per share (in dollars per share)	(0.07)	28.28	(0.23)	28.91
Earnings Per Share, Diluted [Abstract]
Income (loss) from continuing operations (in dollars per share)	(0.03)	(0.02)	(0.19)	0.01
Income (loss) from discontinued operations, net of tax (in dollars per share)	(0.04)	28.31	(0.04)	28.77
Diluted net income (loss) per share (in dollars per share)	$ (0.07)	$ 28.28	$ (0.23)	$ 28.79

Earnings per Share - Anti-dilut

Earnings per Share - Anti-dilutive Securities (Details)	6 Months Ended
	Mar. 31, 2022 shares
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted earnings per share (in shares)	59,513

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregated By Reporting Unit (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 148,401	$ 145,544	$ 326,767	$ 285,196
Life Sciences Products, excluding B Medical
Disaggregation of Revenue [Line Items]
Total revenue	$ 43,738	$ 53,615	$ 91,576	$ 103,493
Reporting unit, name of segment	Life Sciences Products	Life Sciences Products	Life Sciences Products	Life Sciences Products
B Medical
Disaggregation of Revenue [Line Items]
Total revenue	$ 15,122		$ 56,944
Reporting unit, name of segment	Life Sciences Products	Life Sciences Products	Life Sciences Products	Life Sciences Products
Sample Repository Solutions
Disaggregation of Revenue [Line Items]
Total revenue	$ 27,305	$ 26,929	$ 54,921	$ 52,805
Reporting unit, name of segment	Life Sciences Services	Life Sciences Services	Life Sciences Services	Life Sciences Services
Genomic Services
Disaggregation of Revenue [Line Items]
Total revenue	$ 62,236	$ 65,000	$ 123,326	$ 128,898
Reporting unit, name of segment	Life Sciences Services	Life Sciences Services	Life Sciences Services	Life Sciences Services

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Contract Balances (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Sep. 30, 2022
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Accounts receivable, net	$ 167,960		$ 163,758
Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]
Contract assets	22,700		18,200
Contract with Customer, Liability [Abstract]
Contract liabilities	46,000		$ 39,700
Revenue recognized	$ 22,400	$ 18,200

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Remaining Performance Obligations (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 91,460
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 58,944
Unsatisfied performance obligation, period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligations	$ 32,516
Unsatisfied performance obligation, period

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Costs to Obtain and Fulfill a Contract (Details)	Mar. 31, 2023
Capitalized Contract Cost [Abstract]
Sales commission amortization period	60 months

Segment and Geographic Inform_3

Segment and Geographic Information - General Information (Details) - segment	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2	2	2
Number of operating segments	2	2	2	2
Number of reportable segments, previously operated	3	3	3	3

Segment and Geographic Inform_4

Segment and Geographic Information - Acquisitions (Details) - B Medical Systems S.a.r.l and Subsidiaries	Oct. 03, 2022 country
Business Acquisition, Date of Acquisition [Abstract]
Business Acquisition, Effective Date of Acquisition	Oct. 03, 2022
Minimum
Business Acquisition, Date of Acquisition [Abstract]
Number of countries in which entity operates	150

Segment and Geographic Inform_5

Segment and Geographic Information - Reconciliation of Reportable Segment Operating Income (Loss) to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Total revenue	$ 148,401	$ 145,544	$ 326,767	$ 285,196
Amortization of other intangible assets	12,400	7,900	15,900	24,000
Purchase accounting impact on inventory	2,912		5,781
Restructuring charges	1,499	122	2,961	295
Contingent consideration - fair value adjustments	(17,145)	600	(17,145)	600
Tariff adjustment		(486)		(486)
Operating income (loss)	(12,977)	(4,708)	(40,662)	(5,033)
Interest income	10,394	3,076	21,059	3,111
Interest expense		(1,555)		(2,010)
Loss on extinguishment of debt		(632)		(632)
Other income (expense)	(2,668)	(1,170)	(1,523)	(2,248)
Loss before income taxes	(5,251)	(4,989)	(21,126)	(6,812)
Completed Technology
Segment Reporting Information [Line Items]
Amortization of other intangible assets	4,901	1,840	9,070	3,613
Acquired Intangible Assets
Segment Reporting Information [Line Items]
Amortization of other intangible assets	7,509	6,047	14,882	12,319
Life Sciences Products
Segment Reporting Information [Line Items]
Total revenue	58,860	53,615	148,520	103,487
Operating income (loss)	(16,404)	5,288	(20,202)	9,679
Life Sciences Services
Segment Reporting Information [Line Items]
Total revenue	89,541	91,929	178,247	181,709
Operating income (loss)	(4,878)	4,856	(9,490)	12,740
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	148,401	145,544	326,767	285,196
Segment Reconciling Items
Segment Reporting Information [Line Items]
Operating income (loss)	(21,282)	10,144	(29,692)	22,419
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Other unallocated corporate expense (income)	$ (7,981)	$ 7,329	$ (4,579)	$ 11,711

Segment and Geographic Inform_6

Segment and Geographic Information - Financial Information for Business Segments - Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Total assets	$ 3,249,814	$ 3,716,122
Operating Segments
Segment Reporting Information [Line Items]
Total assets	1,797,598	1,228,393
Operating Segments | Life Sciences Products
Segment Reporting Information [Line Items]
Total assets	948,580	378,790
Operating Segments | Life Sciences Services
Segment Reporting Information [Line Items]
Total assets	$ 849,018	$ 849,603

Segment and Geographic Inform_7

Segment and Geographic Information - Reconciliation of Reportable Segment Assets to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Cash and cash equivalents, restricted cash, and marketable securities	$ 1,451,703	$ 2,305,081
Deferred tax asset	490	1,169
Other assets	23	181,479
Assets	3,249,814	3,716,122
Operating Segments
Segment Reporting Information [Line Items]
Assets	$ 1,797,598	$ 1,228,393

Segment and Geographic Inform_8

Segment and Geographic Information - Net Revenues Based upon Source of Order by Geographic Area - Tabular Disclosure (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 148,401	$ 145,544	$ 326,767	$ 285,196
North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	87,484	94,283	176,419	184,366
Rest of Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	21,432	19,745	60,854	40,028
United Kingdom
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	5,789	6,809	11,202	15,121
Africa
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	8,627	672	25,837	1,219
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	11,979	13,757	25,387	26,798
Asia / Pacific / Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 13,090	$ 10,278	$ 27,068	$ 17,664

Segment and Geographic Inform_9

Segment and Geographic Information - Net Revenues Based upon Source of Order by Geographic Area - Additional Information (Details)	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Revenue from Contract with Customer Benchmark | Geographic Concentration Risk, North America [Member] | UNITED STATES
Concentration Risk [Line Items]
Concentration risk (as a percent)	99%	99%	99%	99%

Significant Customers (Details)

Significant Customers (Details)	6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Top Individual Customer | Minimum
Concentration Risk [Line Items]
Concentration risk (as a percent)	10%	10%

Commitments and Contingencies -

Commitments and Contingencies - Tariff Matter (Details) - Tariffs - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2021
Loss Contingency Accrual, Disclosures [Abstract]
Loss contingency accrual		$ 6.1
Loss contingency payment	$ 5.9

Commitments and Contingencies_2

Commitments and Contingencies - Purchase Commitments (Details) $ in Millions	Mar. 31, 2023 USD ($)
Non-cancelable Commitments
Other Commitments [Line Items]
Other commitment	$ 83.5
Non-cancellable Contracts and Purchase Orders for Inventory
Other Commitments [Line Items]
Other commitment	56.3
Non-cancelable Information Technology-related Commitments
Other Commitments [Line Items]
Other commitment	$ 27.2

Commitments and Contingencies_3

Commitments and Contingencies - Contingencies (Details) - Edwards Vacuum LLC, Indemnification, Definitive Agreement, Third-party Warranty Claim - USD ($) $ in Millions	1 Months Ended
	Jan. 31, 2023	Mar. 31, 2023
Loss Contingency, Information about Litigation Matters [Abstract]
Loss contingency, damages sought, value	$ 1
Loss Contingency Accrual, Disclosures [Abstract]
Loss contingency accrual		$ 2.5

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	$ 779,827		$ 1,263,784
Derivative Asset, Statement of Financial Position	Prepaid expenses and other current assets		Prepaid expenses and other current assets
Liabilities, Fair Value Disclosure [Abstract]
Contingent consideration liability	$ 1,400	$ 18,500
Fair Value, Recurring
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	779,827		$ 1,263,782
Foreign exchange contracts	150		634
Net investment hedge	1,278		124,789
Total Assets	1,291,898		1,764,009
Liabilities, Fair Value Disclosure [Abstract]
Contingent consideration liability	1,406
Foreign exchange contracts	164		230
Total Liabilities	1,570		230
Fair Value, Recurring | Cash Equivalents
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	510,643		374,804
Fair Value, Recurring | Fair Value, Inputs, Level 1
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	208,527		651,800
Total Assets	707,810		1,025,855
Fair Value, Recurring | Fair Value, Inputs, Level 1 | Cash Equivalents
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	499,283		374,055
Fair Value, Recurring | Fair Value, Inputs, Level 2
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	571,300		611,982
Foreign exchange contracts	150		634
Net investment hedge	1,278		124,789
Total Assets	584,088		738,154
Liabilities, Fair Value Disclosure [Abstract]
Foreign exchange contracts	164		230
Total Liabilities	164		230
Fair Value, Recurring | Fair Value, Inputs, Level 2 | Cash Equivalents
Assets, Fair Value Disclosure [Abstract]
Cash equivalents	11,360		$ 749
Fair Value, Recurring | Fair Value, Inputs, Level 3
Liabilities, Fair Value Disclosure [Abstract]
Contingent consideration liability	1,406
Total Liabilities	$ 1,406

Fair Value Measurements - Conti

Fair Value Measurements - Contingent Consideration Liability (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Business Combination, Contingent Consideration, Liability [Abstract]
Contingent consideration liability	$ 1.4	$ 18.5

Subsequent Event (Details)

Subsequent Event (Details) - USD ($) shares in Millions			1 Months Ended
	Apr. 05, 2023	Nov. 28, 2022	Apr. 30, 2023	Nov. 04, 2022	Sep. 29, 2015
Share Repurchase Program, September 2015
Subsequent Event [Line Items]
Stock repurchase program, authorized amount				$ 0	$ 50,000,000
Share Repurchase Program, November 2022
Subsequent Event [Line Items]
Stock repurchase program, authorized amount				1,500,000,000
Share Repurchase Program, November 2022, Accelerated Share Repurchase Agreement
Subsequent Event [Line Items]
Stock repurchase program, authorized amount				$ 500,000,000
Stock repurchased and retired during period (in shares)		6.1
Subsequent Event | Share Repurchase Program, November 2022, Accelerated Share Repurchase Agreement
Subsequent Event [Line Items]
Stock repurchased and retired during period (in shares)	4
Subsequent Event | Share Repurchase Program, April 2023
Subsequent Event [Line Items]
Stock repurchase program, authorized amount			$ 500,000,000
Stock repurchased and retired during period (in shares)			10